Podcasts about clarivate

The Stanford Business School professor Michal Kosinski has spent his career warning about the corrosive impact of technology, and particularly social media, on democratic institutions and individual freedom. The Polish born academic gained notoriety for his research at Cambridge University on how social media data could predict intimate personal traits. His work became particularly relevant during the Cambridge Analytica scandal in 2016, leading to significant legal consequences for Facebook, including a $50 billion fine. In this KEEN ON conversation with Kosinski, recorded in Munich at DLD, he emphasizes that Facebook wasn't inherently malicious but failed to understand the full implications of their intrusive technology. Kosinksi connects social media's rise with the growth of populism, explaining how platforms enabled figures like Trump and even Bernie Sanders to bypass traditional political gatekeepers. Kosinski also discusses his controversial 2017 research showing that AI can predict personal characteristics, including sexual orientation, from facial features. On privacy, Kosinski believes that complete privacy protection may be impossible in the modern digital age. Instead, he advocates for building social and legal systems that make privacy invasions less dangerous. Looking to the future, Kosinski expresses short-term optimism about AI's potential to improve lives but long-term concern about the risks of artificial general intelligence (AGI). He notes that while we may see increased prosperity and advancement in the near future, the exponential acceleration of technological progress means long-term risks could materialize much sooner than expected.Michal Kosinski is an Associate Professor of Organizational Behavior at Stanford Graduate School of Business. His research interests encompass both human and artificial cognition. His current work centers on examining the psychological processes in Large Language Models and leveraging Artificial Intelligence, Machine Learning, Big Data, and computational techniques to model and predict human behavior. He co-authored Handbook of Social Psychology and Modern Psychometrics, two popular textbooks, and has published over 100 peer-reviewed papers in prominent journals such as Proceedings of the National Academy of Sciences, Nature Computational Science, Psychological Science, Journal of Personality and Social Psychology, Machine Learning, and Scientific Reports, which have been cited over 22,000 times. He is among the Top 1% of the Highly Cited Researchers according to Clarivate. His research has inspired a cover of The Economist, a 2014 theatre production titled “Privacy,” several TED talks, and a video game. It has been featured in thousands of press articles, books, podcasts, and documentaries. He received a Rising Star award from the Association of Psychological Science (2015) and an Early Achievement Award from the European Association of Personality Psychology (2023). He was behind the first press article warning against Cambridge Analytica. His research exposed the privacy risks they exploited and assessed the effectiveness of their methods. More about his role in uncovering their actions can be found in Steven Levy's insightful book Facebook: The Inside Story and Sander van der Linden's article, “Weapons of Mass Persuasion.” He earned a PhD in psychology from the University of Cambridge and two master's degrees in psychometrics and social psychology. Before his current appointment, he held positions as a post-doctoral scholar in Stanford's Computer Science Department, Deputy Director of the University of Cambridge Psychometrics Centre, and a researcher in Microsoft Research's Machine Learning Group.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting KEEN ON, he is the host of the long-running How To Fix Democracy show. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children.Keen On is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

In this episode, we meet Dr. Sam Gosling, author of "Snoop:  What Your Stuff Says About You" who shares his scientific insights into how personality and character can determine how we express ourselves in our intimate spaces.    Sam Gosling is a Professor of Psychology at the University of Texas, Austin. His research focuses on the psychology of physical space, how personality is expressed in everyday contexts, and on new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in their natural habitats. His current work aims to use psychology to inform architectural practice. His book “Snoop: What your stuff says about you” is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate have identified him as one of the most highly cited scientists in the world.  

Navigating the complexities of groundbreaking treatments can create headwinds. With innovations like Pulsed Field Ablation (PFA) at the forefront, challenges such as financial uncertainties, regulatory shifts, and global adoption become paramount. Join us for an insightful discussion on how global partners address these challenges, focusing on safety & efficacy, financial impacts, and clinical differentiation in areas where baseline data is scarce. Background on PFA: Pulsed Field Ablation (PFA) is a groundbreaking nonthermal energy source that is rapidly transforming atrial fibrillation (AF) treatment, affecting up to 38 million people worldwide. Unlike traditional heat or cold methods, PFA uses high-voltage electrical fields in microseconds for precise cell necrosis, marking a significant advancement in cardiology. Guests: - Juliane Ray, Global Head of Medtech Strategy, Clarivate (Moderator) - Annette Boyle, Editor, BioWorld MedTech - Dee Chaudhary, Principal Commercial Strategy Consulting, Clarivate - Pankhil Ghandhi, Senior Team Lead, Medtech Insights, Clarivate - David Begley, MD, Clinical Director in Cardiology, Royal Papworth HospitalSend us a message! Follow Medical Alley on social media on LinkedIn, Facebook, Twitter and Instagram.

Welcome to Season 2, Episode 86 of The Full Circl Podcast! Gordon Samson shares his journey from a humble Scottish upbringing to becoming the President of Intellectual Property at Clarivate. He discusses the importance of building great teams and the impact of his early life experiences on his personal and professional development. He emphasises the value of intellectual curiosity, learning how to learn, and the significance of relationships in business and personal life. Gordon provides advice for future leaders and encourages inclusivity and openness to diverse perspectives. Thank you for tuning in to this episode of The Full Circl Podcast. We hope you found Gordon's insights valuable and that they inspire you on your own career journey. Stay tuned for more engaging discussions and valuable career advice in future episodes! The Full Circl Podcast takes a closer look into the lives and stories of aspirational leaders worldwide. A range of powerful themes are explored throughout each episode such as; the powerful stories of these Leaders, their pathway to success, and advice to Future Leaders. Find out more at - http://www.circl.org Follow us on Instagram - @‌Circlgram Follow us on LinkedIn - https://linkedin.com/company/circllearning Be sure to like and subscribe for more episodes! Thank you for listening.

In this concluding episode of Season 3 of "Ideas to Innovation," we reflect on our journey through the episodes published in 2024 that highlight the conversations we've enjoyed with some of the brightest minds in education, healthcare and intellectual property law.     In episode 6 in February, we explored America's literacy challenge with documentary filmmaker Jenny Mackenzie. Jenny shared her personal connection to literacy and discussed the innovative strategies being used to promote reading rights across the United States. Her insights into reading proficiency and educational reform were both eye-opening and inspiring.     March brought us a conversation with Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, in episode 7, who detailed the groundbreaking journey of Tarpeyo, a drug that promises to revolutionize the treatment of kidney disease. Renée explained the innovative path to FDA approval, setting new benchmarks in the pharmaceutical industry.     We delved into the impact of artificial intelligence on intellectual property law in episode 8 in April, with Jay Myers from Seyfarth Shaw and Arun Hill from Clarivate. They provided valuable insights into how AI is transforming trademark searches, infringement monitoring and strategic brand decisions while addressing the ethical challenges that come with these advancements.     As we wrap up Season 3, we hope the episodes have informed, inspired, and entertained you. You can also listen to the Season 3 episodes from 2023 – our end-of-year episode summarizes the five stories we shared between September and December.      "Ideas to Innovation" will return later this year with more stories that showcase the power of human intellect and innovation.     Stay curious, and thank you for listening.  

Audio from Day One, Part Three of the 2023 Charleston In Between Today we're featuring Audio from Day One, Part Three of the 2023 Charleston In Between.  In this session, we'll discuss defining integrity standards in publishing. This session is presented by Nadita Quaderi, Clarivate, and was organized and moderated by Sven Fund, Managing Director, Reviewer Credits, and Leah Hinds, Executive Director, Charleston Hub. Video of the presentation available at:  https://youtu.be/2dpB3WERvcY?si=RXlb_GlUIGOYo9WQ Social Media: https://www.linkedin.com/in/nanditaquaderi/ https://www.linkedin.com/in/svenfund/ https://www.linkedin.com/in/leah-hinds-297b31144/ Twitter: Keywords: #Research, #ResearchIntegrity, #ResearchSharing, #PublishingIntegrity, #PeerReview, #AcademicWriting, #ScholarlyWriting, #ScholarlyResource, #AcademicJournal,  #scholcomm, #collaboration,  #engagement, #problemsolvers, #academics, #publishing, #ScholarlyPublishing, #publishingnews, #informationaccess, #AcademicPublishing, #libraries, #librarians, #information, #2023ChsConf,  #LibrariesAndVendors, #libraryvendors, #LibrariesAndPublishers, #libraryissues, #libraryneeds,#librarylove, #librarychallenges, #libraryconference #podcast  

Audio from Day One of the 2023 Charleston In Between Today we're featuring Audio from Day One of the 2023 Charleston In Between.  In this session, we'll discuss why integrity in research and publishing matters, and Institutions, libraries and their roles in research integrity. Also, how to define integrity standards in publishing with integrity. This session is presented by Mohammed Hosseini,  Northwestern University, Curtis Brundy of Iowa State University, and Nadita Quaderi, Clarivate. The session is organized and moderated by Sven Fund, Managing Director, Reviewer Credits, and Leah Hinds, Executive Director for the Charleston Hub. Video of the presentation available at:  https://www.youtube.com/watch?v=3DSmTRjDkIE&t=38s Social Media: https://www.linkedin.com/in/hosseinimohammad/ https://www.linkedin.com/in/curtisbrundy/ https://www.linkedin.com/in/nanditaquaderi/ https://www.linkedin.com/in/svenfund/ https://www.linkedin.com/in/leah-hinds-297b31144/ Twitter: Keywords: #Research, #ResearchIntegrity, #ResearchSharing, #PublishingIntegrity, #PeerReview, #AcademicWriting, #ScholarlyWriting, #ScholarlyResource, #AcademicJournal,  #scholcomm, #collaboration,  #engagement, #problemsolvers, #academics, #publishing, #ScholarlyPublishing, #publishingnews, #informationaccess, #AcademicPublishing, #libraries, #librarians, #information, #2023ChsConf,  #LibrariesAndVendors, #libraryvendors, #LibrariesAndPublishers, #libraryissues, #libraryneeds,#librarylove, #librarychallenges, #libraryconference #podcast  

Welcome to today's episode of 'AI Lawyer Talking Tech'! In this installment, we delve into the transformative power of artificial intelligence across the legal industry. We'll explore groundbreaking platforms like Clarivate's Academic AI, innovative tools from Microsoft's Build 2024, and the integration of AI in law firms for sustainable growth. Additionally, we'll discuss the ethical implications and regulatory challenges posed by AI adoption, ensuring a balanced perspective on this rapidly evolving landscape. Join us as we uncover how AI is reshaping legal practices, enhancing research, and driving strategic advancements, all while navigating the fine line between innovation and ethical responsibility. Stay tuned for a comprehensive look at the latest trends and developments in legal technology. Introducing the Clarivate Academic AI Platform23 May 2024Stephen's LighthouseJustia CLE & Webinars: From Billable Hours to Sustainable Income22 May 2024Legal Marketing & Technology Blog10 things a GC thinks about AI and the law22 May 2024Thomson Reuters InstituteTop AI Announcements at Microsoft Build 202422 May 2024Stephen's LighthouseCrucial AI safety breakthrough: 16 major AI companies have agreed to commit to a set of AI safety standards22 May 2024Stephen's LighthouseLawyerist Podcast #506: Managing Stress & Avoiding Burnout, with Emily Nagoski (Replay)23 May 2024Legal Talk NetworkAustria: Artificial intelligence and HR compliance – What to consider?21 May 2024Global Compliance News2023-2030 Legal Services Procurement Intelligence: Achieving Competitive Advantages23 May 2024Express Press ReleaseHeadlong rush in health care to embrace AI opens trap door to legal disputes23 May 2024Genetic Literacy ProjectEthical Issues Around AI Use in the Legal Industry22 May 2024Firsthand.coRipple's Legal Showdown: CLO Fires Shots at SEC Chair Gensler22 May 2024Crypto News FlashRecreating historic Brown v. Board case with technology22 May 2024The Blog HeraldOverview of state digital privacy regulations22 May 2024Reason FoundationThe Real Reasons AI Can't Replace Real Estate Professionals22 May 2024Florida RealtorGenAI for corp legal: What to do this year22 May 2024Financial Thomson ReutersYou Are Not Hallucinating22 May 2024CLM MagazineUnlocking effective spend management: Strategies for controlling corporate legal expenses22 May 2024Financial Thomson Reuters9 legal malpractice trends in 202422 May 2024ABA JournalHow Savvy Lawyers Build Their Law Firm Rate Sheet [Sponsored]22 May 2024Above The LawExecutives who use AI for hiring must 'be vigilant' about reducing bias — or risk landing in hot water, says a labor attorney22 May 2024AOL.comTravers Smith spins out AI technology products into new software business22 May 2024The Global Legal Post6 Strategies for Recruiting Top Legal Talent22 May 2024National Law ReviewReasons Why OpenAI should be Afraid of Facing a Lawsuit from Scarlett Johansson22 May 2024West ObserverINZMO Launches RentalBot to Ease Dispute Tensions Between Tenants and Landlords22 May 2024Fintech TimesVoice cloning recreates historic Supreme Court case22 May 2024The Blog HeraldLawyerist Podcast #505: Get to Inbox Zero with the Help of a Virtual Assistant, with Stafi22 May 2024Legal Talk NetworkASU Law, Diné College, Navajo Nation partner on first-ever tribally affiliated legal program22 May 2024Arizona State UniversityLevine Leichtman Capital Partners and ICG Announce Strategic Partnership with Law Business Research22 May 2024Levine Leichtman Capital PartnersGavel Accelerates Adoption of AI for Legal Field, Celebrates Customer Achievements, and Launches GPT-4o22 May 2024Fox8Key Insights from the Corporate Counsel Summit 202422 May 2024JD SupraStates Begin To Regulate AI in Absence of Federal Legislation22 May 2024Perkins Coie

The BRAND NEW 2nd Generation Tone Devices are NOW SHIPPING!! Order HERE Hi friends! This episode is featuring Dr. Stuart Phillips! See full bio below. WIN $800 in Energybits and a Tone LUX Diamond red light therapy panel! Contest details HERE Get 20% OFF Energybits Spirulina and Chlorella with the code KETOGIRL Energybits.com Get $50 OFF The Tone LUX Red Light Therapy Panels when combined with a pre-order for the new Tone LUX Crystal Mask - use the code TONELUXSAVE50 - Click HERE To Shop! Now available! Tone Protein- Click Here to Check it out! - Follow @optimalproteinpodcast on Instagram to see visuals and posts mentioned on this podcast. Follow Vanessa on instagram to see her meals, recipes, informative posts and much more! Click here @ketogenicgirl Link to join the facebook group for the podcast: https://www.facebook.com/groups/2017506024952802/   Stuart Phillips obtained a Ph.D. from the University of Waterloo in Human Physiology in 1995. He joined McMaster University in 1999 and is currently a full Professor in the Department of Kinesiology and School of Medicine at McMaster University. He is Tier 1 Canada Research Chair in Skeletal Muscle Health. He is also the Director of the McMaster Centre for Nutrition, Exercise, and Health Research and the Physical Activity Centre of Excellence. Dr. Phillips has authored more than 200 original research papers and 75 reviews. In 2018 and 2019, he was named to Clarivate's Highly Cited Researchers he list as a being in the top 1% of all cited researchers in nutrition and exercise research. Dr. Phillips is a fellow of the American College of Sports Medicine and the Canadian Academy of Health Sciences. - This podcast content does not constitute an attempt to practice medicine and does not establish a doctor-patient relationship. Please consult a qualified healthcare provider for medical advice and personal health questions. Prior to beginning a new diet you should undergo a health screening with your physician to confirm that a new diet is suitable for you and to out any conditions and contraindications that may pose risks or are incompatible with a new diet, including by way of example: conditions affecting the kidneys, liver or pancreas; muscular dystrophy; pregnancy; breast-feeding; being underweight; eating disorders; any health condition that requires a special diet [other conditions or contraindications]; hypoglycemia; or type 1 diabetes. A new diet may or may not be appropriate if you have type 2 diabetes, so you must consult with your physician if you have this condition. Anyone under the age of 18 should consult with their physician and their parents or legal guardian before beginning such a diet. Use of Ketogenic Girl videos are subject to the Ketogenicgirl.com Terms of Use and Medical Disclaimer. All rights reserved. If you do not agree with these terms, do not listen to, or view any Ketogenic Girl podcasts or videos.

Today we continue our discussion in part two about the relationship between our stuff and our personal identities with Dr. Sam Gosling. Sam Gosling is a Professor of Psychology at the University of Texas, Austin. He did his doctoral work at the University of California at Berkeley, where his dissertation focused on personality in spotted hyenas. His current research focuses on the psychology of physical space, how personality is expressed in everyday contexts in daily life, and in new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in the contexts of their natural habitats. He is an elected fellow of the Association for Psychological Science and Society for Personality and Social Psychology (or SPSP for short). Dr. Gosling is the recipient of the American Psychological Association's Distinguished Scientific Award for Early Career Contribution, the Carol and Ed Diener Award in Personality Psychology, and SPSP's award for methodological innovation. His book, “Snoop: What your stuff says about you” which we'll also discuss, is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate, which is global leader in providing trusted insights and analytics, have identified him as one of the most highly cited scientists in the world. SOURCES: https://docs.google.com/document/d/1VbPjsPW26ZUte4wkH9h3s2TmcBHPOp_yTBgVq3C2AHk/edit?usp=sharing MUSIC: "Sun Shines Through the Leaves" --- ©2022, ©2024 The Furious Curious

The remarkable journey of Calliditas Therapeutics and its groundbreaking drug, Tarpeyo, sheds light on the company's innovative strategies and relentless pursuit of excellence that led to the successful approval of Tarpeyo by the U.S. Food and Drug Administration (FDA) for the treatment of a specific kidney disease. Our guest in this episode, Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, reveals how their pioneering approach to drug development has set a new benchmark in the pharmaceutical industry.  We explore how Calliditas Therapeutics' groundbreaking work in securing FDA approval not only marks a significant milestone for the company but also inspires a new wave of innovation in the treatment of kidney diseases. Discover the power of pioneering drug development and the bright future it heralds for patients worldwide.  This episode also features insights from Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, highlighting the importance of the Drugs to Watch 2024 report and the potential of Tarpeyo – one of 13 drugs to watch included in the report – to significantly improve patient outcomes.  Discover a story of resilience, innovation, and success behind Tarpeyo's journey to the American market, and the broader implications for the pharmaceutical industry's approach to drug development and regulatory approval. 

Welcome to the "AI Lawyer Talking Tech" podcast, where we delve into the latest developments at the intersection of artificial intelligence and the legal industry. Today's episode explores the dynamic landscape of AI in the legal sphere, from the integration of generative AI to the ongoing AI copyright war. We'll delve into pivotal trends that are shaping the future of law firms and legal teams, including the rise of AI in compliance management, equity regulation, and the European Central Bank's efforts to leverage AI for banking supervision. Join us as we unpack the transformative impact of AI on the legal tech landscape, including the ethical considerations and legal implications that accompany these technological advancements. Optimizing Social Media for Law Firms: What Content to Post on Each Platform04 Mar 2024JD Supra3 Trends Transforming the Future of Law Firms and Legal Teams04 Mar 2024New York State Bar AssociationStability files defence in important test case on AI and UK copyright law04 Mar 2024Complete Music UpdateUnearthing The Gold: The Art And Science Of Discovering Use Cases In Legal Tech04 Mar 2024Above The LawNews outlets vs OpenAI: The AI copyright wars have begun04 Mar 2024DataconomyAI Briefing: Elon Musk and Sam Altman battle over OpenAI's mission04 Mar 2024DigidaySlice: Continuous Compliance Platform Company Secures $7 Million03 Mar 2024Pulse 2.0Google's AI Controversy, Apple's Shift In Focus, And Musk's Legal Battle Against OpenAI: This Week In AI03 Mar 2024Benzinga.comElon Musk's Lawyers Request $6 Billion in Tesla Shares as Legal Fees02 Mar 2024CryptopolitanBig Four accountants ban job applicants from using AI02 Mar 2024AOL UK'AI won': Judges caution lawyers to educate themselves about artificial intelligence in the law02 Mar 2024Colorado Springs GazetteFTC Warns About Changing Terms of Service or Privacy Policy to Train AI on Previously Collected Data01 Mar 2024National Law ReviewDOJ and FTC Update Preservation Specifications for Second Requests01 Mar 2024JD SupraEuropean Central Bank sees supervisory boost from generative AI04 Mar 2024Thomson Reuters InstituteLFFI Q4 2023 analysis: Will the growth pattern law firm rates saw in 2023 continue into 2024?04 Mar 2024Thomson Reuters InstituteProQuest, part of Clarivate, launches AI-powered research assistant03 Mar 2024Stephen's LighthouseNavigating the New Frontier: Insurance for Artificial Intelligence Risks04 Mar 2024K&L GatesNTIA seeks comment on availability of model weights in highly capable AI systems04 Mar 2024Hogan LovellsLitigation and Investigation Implications for Companies Adopting GenAI04 Mar 2024SkaddenTelephone and Texting Compliance News: Regulatory Update — FCC Confirms TCPA Bars AI-Generated Voices, Adopts New Consent Revocation Rights Rules for Texts, Cuts 13 Entities from Robocall Mitigation Database01 Mar 2024Mintz Levin

Success lies in adapting products based on real-world feedback, ensuring your business aligns with your customers' genuine desires. This is exactly what Chris Takcas, Sales Manager at Clarivate and host Marc Gonyea sit down to discuss in the latest episode of Tech Sales is for Hustlers, outlining the need for products and businesses to be user-centric, rather than just technically sound.  Chris talks about how he goes about adapting products based on feedback, highlighting the importance of user-friendly interfaces. Not only that, but he shares his evolution from transactional to solution-based sales, emphasizing the value of diagnosing customer problems holistically. Chris also underscores the role of coaching in sales growth, drawing parallels between managing a gym and nurturing sales talent.

For nearly half a century, the Journal Citation Reports, or JCR, have been “must reading” in universities around the world. Dr. Nandita Quaderi, a senior vice president and the editor in chief for Web of Science at Clarivate, shares the latest developments in the JCR's ongoing evolution.

Audio from the 2023 Charleston Conference Leadership Interview Series. Heather Staines, Senior Strategy Consultant, Delta Think and a Director for the Charleston Conference interviews Bar Veinstein, President, Academia & Government, Clarivate. Heather and Bar talk about his background and how he came to join Clarivate in a newly created position last year, how technology in libraries has changed and how libraries have been change agents as early adopters of technology ahead of other industries, not just in the libraries but beyond campus. He says Clarivate's mission is to offer services to help libraries expand beyond the core for libraries to be successful. Bar says Clarivate is constantly searching for ways to help the library engage and interact with other stakeholders on campus to show and extend the value of the libraries to help everyone be successful. Bar also talks about his experiences with the Charleston Conference and the keynote panel presentation on the need for scholarly publishing and the impact of open research. Video of the Interview is available at: https://www.youtube.com/watch?v=6_ZEzByVSiI  Social Media: LinkedIn: https://www.linkedin.com/in/heatherstaines/ https://www.linkedin.com/in/barveinstein/ Keywords:   #Clarivate, #technology, #innovation, #AI, #GenAI, #thinkforward, #LeadershipDevelopment, #entrepreneurship, #leaders, #leadership, #2023ChsConf, #libraries, #librarianship, #LibraryNeeds, #LibraryLove, #ScholarlyPublishing, #AcademicPublishing, #publishing, #LibrariesAndPublishers, #podcasts

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have a jam-packed episode with the latest news and trends in the industry. Let's dive in!In the pharmaceutical industry, drugmakers are facing five important questions in 2024. These include competition in obesity, the next era of oncology, and the impact of a contentious drug pricing law. Pfizer had a difficult year in 2023, but we had the opportunity to hear from Albert Bourla, the company's CEO, about their plans for the future. PureTech's Daphne Zohar is also making waves with her neuroscience startups. Despite layoffs in the biotech industry, recent deal-making and stock market momentum have brought some optimism. Biotech mergers and acquisitions are picking back up, with $45 billion worth of deals announced in the past six weeks. We also have sponsored content about leveraging artificial intelligence in patient support and real-world data in clinical trials.Switching gears to healthcare, hospitals are facing slim operating margins and experts predict they will focus on trimming unnecessary expenses and investing strategically in labor. The Department of Health and Human Services has published an updated provider conscience rule, balancing religious freedom rights with patients' access to care. The Federal Trade Commission has reached a settlement with a data broker to protect patients' privacy. Sutter Health has appointed a new CFO, Raju Iyer, who will be responsible for financial planning. And don't forget about FedEx Office's sponsored content on how high-quality printed materials can boost patient relationships.In biotech news, Myrobalan has raised $24 million to advance its neurorestorative drugs for neurological disorders. Alcon has reported promising data from a Phase III trial for its drops to treat dry eye disease. Taco Bell is hosting a Las Vegas fan experience ahead of Super Bowl LVIII, showcasing new products and partnerships. Walmart+ has enlisted TV personality Andy Cohen for its "Quitter's Day" campaign. Honda has launched its "Chasing Greatness" campaign featuring indie artist Bishop Briggs. And we have the top 50 content marketing brands and eight predictions for 2024 in the marketing industry.Two biotech companies, 4D Molecular Therapeutics and Arbor Biotechnologies, have announced a collaboration to develop treatments for central nervous system diseases. We also discuss the potential of artificial intelligence in drug discovery and development. And we wrap up with news on pharmaceutical companies using tactics to maintain high drug prices, Clarivate's "drugs to watch" list for 2024, and various acquisitions and layoffs in the biopharma industry.Abzena is offering a new application note for its Thiobridge™ technology in ADC development, highlighting improved stability and efficacy. Medtronic is focused on delivering durable revenue and profit growth, while Dexcom plans to launch a new CGM device. Amazon has launched a chronic condition management portal, and Walgreens has settled a drug pricing dispute with Humana. Nonprofit hospitals and health systems are financially stable despite declining operating margins. And digital health funding reached its lowest level since 2019.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more news and updates in the industry. Remember, we give you only what's important to hear!

Over the past year, the Ideas to Innovation podcast from Clarivate took listeners on a special journey through a world where curiosity meets ingenuity. In each of 15 episodes published in 2023, we told stories of people thinking forward in the real world, highlighting those who not only dared to dream but also transformed their dreams into reality. Our conversations with experts weren't just talks; they were narratives of change, powerful examples of how fresh insights are solving some of the world's most complex challenges.   For this “Best of 2023” episode, we showcase three compelling stories, each of which serves a testament to the spirit of innovation. You'll first hear from an associate professor who is known as a ‘scientific sleuth' for his uncanny ability to identify falsified data in published academic research. Next, two guests share their stories about a rare hereditary disease, its devastating impacts and the role and work of scientific research in finding answers. In our final segment, an accomplished scientist, engineer, and innovator with 77 patents to her name talks about her work in breaking down complex problems, her most surprising discovery, and finding solutions that stick. We hope you enjoy this recap and continue joining us as we traverse a landscape rich in creativity and innovation, meeting extraordinary minds and witnessing their groundbreaking work in real time. 

Rapid advancements in technology and science are shaping a new era, with artificial intelligence and synthetic biology, or “syn-bio,” at the forefront. Heralded as the next big leap in science, syn-bio involves redesigning organisms for useful purposes by engineering them to have new abilities. The importance of syn-bio for people and our planet cannot be overstated. It offers novel ways of producing almost anything that human beings consume, from flavors and fabrics to foods and fuels. Today, the combination of syn-bio and AI – two of the most potent realms of science and technology – promises to unravel solutions to our most pressing challenges, including Earth's food and water, the environment and sustainability, bioenergy, and human health care.  One widely recognized trailblazer in syn-bio is Jim Collins, professor of medical engineering and science and professor of biological engineering at MIT. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. In the latest episode of the “Ideas to Innovation Season 3” podcast from Clarivate, Collins helps listeners navigate through the exciting but complex landscape of syn-bio. He also discusses what it was like to be named a Citation Laureate 2023 for his pioneering work in synthetic gene circuits, which launched the field of syn-bio. Each year since 2002, the Citation Laureates program from Clarivate recognizes a small group of highly cited scientists and economists whose influence is comparable to that of past and future Nobel Prize winners. 

Mark Garlinghouse Director, Business Development @The Lens Mark Garlinghouse is responsible for business development at The Lens. He joined The Lens in 2019 to support its transition to financial sustainability. Mark has over 25 years of experience in the information industry, working with Information Handling Services (now S&P Global Engineering Solution) and the Institute for Scientific Information/Thomson Reuters (now Clarivate) in various business development and leadership roles. Aaron Ballagh Manager, Scholarly Content @The Lens Aaron is the Scholarly Content Manager for The Lens. Starting his career in fisheries research, Aaron moved into research information management when he joined the Research Services team at James Cook University as a research data and systems analyst. He then joined the Research Services Division at The Australian National University working on the university's research information systems to analyze and model research performance. As research data manager, Aaron submitted the Excellence in Research for Australia submission for ANU before joining Springer Nature as data product manager for the Nature Index. About the webinar series This webinar series is co-organised by: UbuntuNet Alliance: https://ubuntunet.net/ and Access 2 Perspectives: https://access2perspectives.org/ as part of the ORCID Global Participation Program: https://info.orcid.org/global-participation-program/ The Global Participation Fund: https://info.orcid.org/global-participation-program/global-participation-fund/ Learn more about ORCID: https://orcid.org/ Link to the webinar series: https://africarxiv.pubpub.org/webinars AfricArXiv website: africarxiv.org ⁠ORCID⁠ is the persistent identifier for researchers to share their accomplishments (research articles, data, etc with funding agencies, publishers, data repositories, and other research workflows. ⁠AfricArXiv⁠ is a community-led digital archive for African research communication. By enhancing the visibility of African research, we enable discoverability and collaboration opportunities for African scientists on the continent as well as globally. Find more podcast episodes here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://access2perspectives.pubpub.org/podcast⁠⁠⁠⁠⁠⁠⁠ Host:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr Jo Havemann⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ORCID iD ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠0000-0002-6157-1494 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Editing: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ebuka Ezeike⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Alex Lustig⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Kitty Kat ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ License:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Attribution 4.0 International (CC BY 4.0)   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ At Access 2 Perspectives, we guide you in your complete research workflow toward state-of-the-art research practices and in full compliance with funding and publishing requirements. Leverage your research projects to higher efficiency and increased collaboration opportunities while fostering your explorative spirit and joy. Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://access2perspectives.pubpub.org⁠⁠⁠⁠⁠⁠⁠ --- Send in a voice message: https://podcasters.spotify.com/pod/show/access2perspectives/message

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Pinduoduo macht Konkurrenten arm und den Gründer reich. RWE macht seine Aktionäre reich, und das am besten mit grüner Energie. Shein will sich Reichtum an der Börse holen. Clarivate (WKN: A2PLSH) hat enorm viele Forschungsdaten und seit neuestem das Orakel von Boston an Bord. Kommt jetzt der Turnaround? Airbnb (WKN: A2QG35) ist eigentlich eine Bank. Diesen Podcast vom 29.11.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Over the past half century, the semiconductor technology landscape has been evolving rapidly, underpinning the digital transformations we witness across the various spheres of life today. Sometimes referred to as integrated circuits or microchips, semiconductors are the backbone of modern electronics. In devices of every type, from simple gadgets to complex systems like computers, cars and household appliances, semiconductors have led to them being smaller or faster or more reliable. More inconspicuously, semiconductors are now enabling innovations in healthcare to flourish.    One company, imec, stands as a vanguard in this area. Their work promises to enable smart health concepts such as precision medicine and genomics to be brought within everyone's reach, resulting in personalized treatments with better outcomes and lower costs. Joining the latest episode of the “Ideas to Innovation Season 3” podcast from Clarivate is Peter Peumans, Chief Technology Officer - Healthcare Technologies and Senior Fellow at Belgium-based imec.  He and Ed White of Clarivate discuss how innovations in semiconductors led imec to be named one of 36 companies in this year's Innovators to Watch report from Clarivate. The report – guided by Ed in his role as vice president and principal analyst for IP and Innovation Research at Clarivate –identifies organizations that demonstrate both exceptional potential and above-the-bar innovation excellence. 

Books  (2023) Gender-Based Violence: A Comprehensive Guide. Springer International Publishing.  Ali P (2019) Preface.   Edited books Hinsliff-Smith K, McGarry J & Ali P (Eds.) (2022) Arts Based Health Care Research: A Multidisciplinary Perspective. Springer International Publishing.   Ali P & McGarry J (Ed.) (2020) Domestic Violence in Health Contexts: A Guide for Healthcare Professions. Springer International Publishing.   Journal articles Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGO, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the Risks of Nuclear War: the Role of Health Professionals.. Cerebellum.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGO, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the risks of nuclear war - the role of health professionals.. Rev Saude Publica, 57, 1ed.   Rogers MM, Ali P, Thompson J & Ifayomi M (2023) “Survive, learn to live with it … or not”: A narrative analysis of women's repeat victimization using a lifecourse perspective. Social Science & Medicine, 338, 116338-116338.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Horton R, Mash R, Monteiro C, Naumova EN, Rubin EJ , Sahni P et al (2023) Reducing the risks of nuclear war—the role of health professionals. Blood Cancer Journal, 13(1), 159.   Zlotnick C, Patel H, Ali P, Odewusi T & Luiking M-L (2023) Globalization: Migrant nurses' acculturation and their healthcare encounters as consumers of healthcare. Nursing Inquiry.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Horton R, Mash R, Monteiro C, Naumova EN, Rubin EJ , Sahni P et al (2023) Reducing the risks of nuclear war—the role of health professionals. Supportive Care in Cancer, 31(10).   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Gong P, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the Risks of Nuclear War: The Role of Health Professionals. American Journal of Psychiatry, 180(10), 712-713.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the Risks of Nuclear War — The Role of Health Professionals. New England Journal of Medicine, 389(12), 1066-1067.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war: the role of health professionals. European Heart Journal - Imaging Methods and Practice, 1(2).   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war: the role of health professionals. International Journal for Quality in Health Care, 35(3).  Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war—the role of health professionals. Tidsskrift for Den norske legeforening.  Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war: the role of health professionals. European Heart Journal - Case Reports, 7(9).   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war: the role of health professionals. Brain Communications, 5(5).   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war: the role of health professionals. IJQHC Communications, 3(2).   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war: the role of health professionals. Europace, 25(9).   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the risks of nuclear war—The role of health professionals. Journal of Medical Imaging and Radiation Sciences.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the risks of nuclear war: the role of health professionals. Journal of Public Health Policy, 44(3), 344-347.    (2023) REDUCING THE RISKS OF NUCLEAR WAR – THE ROLE OF HEALTH PROFESSIONALS. Journal of Postgraduate Medical Institute.   Abbasi K, Ali P, Barbour V, Bibbins‐Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Horton R, Mash B , Mitra A et al (2023) Reducing the risks of nuclear war—the role of health professionals. Reproductive, Female and Child Health, 2(3), 121-123.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Gong P, Haines A, Helfand I, Richard H, Mash B , Mitra A et al (2023) Reducing the Risks of Nuclear War—the role of Health Professionals ‎. Afro-Egyptian Journal of Infectious and Endemic Diseases, 0(0), 143-145.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the Risks of Nuclear War—the Role of Health Professionals. Journal of Exploratory Research in Pharmacology, 000(000), 000-000.  Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the risks of nuclear war—the role of health professionals. The Lancet, 402(10400), 431-433.  Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Haines A, Helfand I, Horton R, Mash B, Mitra A , Monteiro C et al (2023) Reducing the Risks of Nuclear War—The Role of Health Professionals. JAMA, 330(7), 601-601.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Olde Rikkert MGM, Horton R, Mash, R, Monteiro C, Naumova EN, Rubin EJ , Sahni P et al (2023) Reducing the risks of nuclear war—The role of health professionals. Complementary Therapies in Medicine, 102967-102967.   Ali P (2023) The importance of highlighting effective practice. Nursing Management, 30(3), 19-19.   Hayter M, Lee A, Dixit A, Rasalpurkar S, Fewings H, Ali P, Whitfield C, Giridhari S, Kabra P, Rayamane K , Ovseiko P et al (2023) Experiences of domestic violence prevention interventions and gender equality promotion work: a qualitative study of Nirdhar Groups in rural India. F1000Research, 12.   Younas A, Fàbregues S, Durante A, Escalante EL, Inayat S & Ali P (2023) Proposing the “MIRACLE” Narrative Framework for Providing Thick Description in Qualitative Research. International Journal of Qualitative Methods, 22, 160940692211471-160940692211471.   Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Gong P, Haines A, Helfand I, Richard H, Mitra A , Monteiro C et al (2023) Reducing the Risks of Nuclear War—The Role of Health Professionals. African Journal of Gastroenterology and Hepatology, 6(1), 118-121.   Unsworth J, Greene K, Ali P, Lillebø G & Mazilu DC (2022) Advanced practice nurse roles in Europe: implementation challenges, progress and lessons learnt. International Nursing Review.   Ali P (2022) The importance of highlighting effective practice. Nursing Management, 29(3), 17-17.   Rogers MM, Fisher C, Ali P, Allmark P & Fontes L (2022) Technology-Facilitated Abuse in Intimate Relationships: A Scoping Review.. Trauma Violence Abuse, 15248380221090218.   Mikton C, Beaulieu M, Yon Y, Genesse JC, St‐Martin K, Byrne M, Phelan A, Storey J, Rogers M, Campbell F , Ali P et al (2022) Protocol: Global elder abuse: a mega-map of systematic reviews on prevalence, consequences, risk and protective factors and interventions. Campbell Systematic Reviews, 18(2). View this article in WRRO   Shahzad S, Younas A & ALI P (2022) Social justice education in nursing: An integrative review of teaching and learning approaches and students' and educators' experiences. Nurse Education Today, 110, 105272-105272.   Meherali S, Adewale B, Ali S, Kennedy M, Salami BO, Richter S, Okeke-Ihejirika PE, Ali P, da Silva KL, Adjorlolo S , Aziato L et al (2021) Impact of the COVID-19 pandemic on adolescents' sexual and reproductive health in low- and middle-income countries. International Journal of Environmental Research and Public Health, 18(24).  Ali P (2021) Nursing beyond the pandemic: Resilience and determination will shape our future options. International Nursing Review, 68(4), 435-436.  Watson R, Younas A, Rehman SA & Ali PA (2021) Clarivate listed nursing journals in 2020: what they publish and how they measure use of social media. Frontiers of Nursing, 8(4), 429-436.  Naz S, Muhammad D, Ahmad A, Shabnam & Ali P (2021) Pregnant women perceptions regarding their husbands and in-laws' support during pregnancy: a qualitative study. The Pan African Medical Journal, 39.  Jony SSR, Haque U, Webb NJ, Spence E, Rahman MS, Aghamohammadi N, Lie Y, Angulo-Molina A, Ananth S, Ren X , Kawachi N et al (2021) Analyzing predictors of control measures and psychosocial problems associated with COVID-19 pandemic: evidence from eight countries. Behavioral Sciences, 11(8).  Darbyshire P, Thompson DR, Watson R, Jenkins E & Ali P (2021) Academic Freedom. Journal of Nursing Education, 60(7), 367-368.  Ahankari A, Hayter M, Whitfield C, Ali P, Giridhari S, Tambe S, Kabra P, Rayamane K & Ovseiko P (2021) aDolescents gEnder surVey, rEsponsible coupLes evaluatiOn, and capacity building Project in India (DEVELOP): a study protocol. F1000Research, 8, 958.  Keynejad RC, Bentley A, Bhatia U, Nalwadda O, Mekonnen FD, Ali PA & McGarry J (2021) Research, education and capacity building priorities for violence, abuse and mental health in low- and middle-income countries: an international qualitative survey. Social Psychiatry and Psychiatric Epidemiology.

Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s.

The concept of academic libraries has evolved from humble beginnings five thousand years ago to the expansive network that exists today in public schools, colleges, and universities across the United States. It's easy to see why libraries are worth supporting. They continue to facilitate academic excellence, embrace advancements in technology and foster community and collaboration. Still, looking ahead, academic libraries face several significant challenges, including – perhaps most importantly – the significant cost for their support.     Championing the cause of libraries is the mission of our latest guest on the “Ideas to Innovation Season 3” podcast from Clarivate. John Chrastka serves as executive director of EveryLibrary, a non-profit group that builds voter support for academic libraries and helps them secure funding as well. To advance this mission, Clarivate recently announced a partnership with EveryLibrary that leverages the strengths of the two organizations through dedicated resources and advocacy. John is long-time library trustee, supporter and advocate for academic libraries. Prior to his current role, he served as former partner in AssociaDirect, a Chicago, Illinois-based consultancy focused on support associations in membership recruitment, conference, and governance activities. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.In our first news, we have a summary of an on-demand webinar that discusses how real-world data (RWD) can be leveraged in rare disease research. The use of RWD in clinical trials and drug development for rare diseases is explored by experts from Pfizer and Clarivate. They highlight the importance of RWD in narrowing the gap of knowledge surrounding rare diseases and how it can enhance clinical trials and improve drug development processes. Challenges associated with harnessing RWD effectively are also addressed, along with best practices for overcoming these obstacles. The goal is to optimize rare disease research by leveraging RWD and improving drug development efficiency.Moving on to our next news, we have a promotion for an on-demand webinar titled "High-Throughput Process & Analytical Platforms to Accelerate Gene Therapy Scale-Up." This webinar discusses various topics related to gene therapy scale-up and how innovative platforms can revolutionize the process. Some key points covered include serotype agnostic analytics for AAV manufacturing, challenges in scaling up to larger bioreactors, using an advanced platform with a reduced number of plasmids, and Resilience and Lacerta's innovations. Experts in the field share their insights, and interested individuals can connect with the Resilience team for support in gene therapy process and analytical development work.In regulatory news, the FDA has placed a partial clinical hold on two studies of Innate Pharma's investigational therapy lacutamab following a patient death from the rare blood disease hemophagocytic lymphohistiocytosis. Innate Pharma is working closely with the FDA to address the agency's concerns and provide the necessary data. In other news, an FDA advisory committee has backed the use of US WorldMeds' investigational drug for high-risk neuroblastoma, despite the lack of a randomized controlled trial. This decision could set a precedent for future drug approvals without randomized controlled trial data. Japan-based pharma company Kyowa Kirin is also acquiring Orchard Therapeutics pending regulatory approvals, and Johnson & Johnson's spravato has shown promising results in a phase III head-to-head study.Shifting gears to marketing and advertising, we discuss the importance of connected TV for marketers and how the Hollywood shutdown could disrupt the ad market. Disney's innovative holiday marketing strategies are highlighted, along with Olaplex's unique approach to addressing dupe culture on TikTok. Three Olives Vodka is mentioned for using AI to plan the perfect party, and Meta (formerly known as Facebook) is expanding access to its generative AI tools. Target has launched an immersive toy experience for online shoppers, allowing them to explore a virtual room of products.In the rare disease space, we delve into regulatory challenges related to the use of biomarkers to measure efficacy. The FDA recently approved Novo Nordisk's drug rivfloza for patients with primary hyperoxaluria, but there are concerns about shortcomings in regulatory policies when it comes to biomarkers for rare diseases. Leaders in the pharmaceutical industry who are skilled at translating scientific research into products that regulators see value in are recognized on this year's Pharmavoice 100 list.Lastly, we address the challenges faced by health systems in their workforce due to a volatile economy. Burnout and high turnover rates persist despite efforts to raise wages and strengthen hiring. The nursing shortage is a major issue, and efforts are being made to address the gender pay gap among physicians. On a positive note, there has been a record number of residency matches for 2023, providing insights into current labor trends in healthcare.That wraps up today's episode of Pharma and Biotech daily. Stay tuned for more important news and updates in

Artificial intelligence is all around us and it's revolutionizing our world in many ways. In life sciences and healthcare, AI-powered technologies are instrumental in tasks such as diagnostics, precision medicine and even robotic surgery. And the transformative aspect of generative AI is already being felt in areas such as pharmaceutical research, epidemiology and telemedicine. There are projections that the global market for AI in life sciences and healthcare will be $6.7 billion USD by 2030. What is driving such remarkable growth and how rosy is this picture?     Joining us at the start of a new season three of the “Ideas to Innovation” podcast from Clarivate is Henry Levy, who has plenty to say about AI and what it will and won't enable us to achieve. Henry joined Clarivate earlier this year as President, Life Sciences and Healthcare (LS&H). He leads the teams focused on developing solutions that enable life sciences and healthcare companies and providers to create a healthier tomorrow by connecting them to transformative intelligence and data technology to improve patient lives. With more than 25 years of experience, Henry is the author of multiple articles on drug development and tech trends and a frequent speaker at industry forums. He holds a bachelor's degree in bioengineering from the University of Pennsylvania.

Today, innovation is key to driving business growth and competitive advantage, with intellectual property or IP sitting at the very heart of this strategy. In recent years we've witnessed some remarkable strides across the globe in bridging the gender gap in the IP sector. Yet, according to the World Intellectual Property Organization, only 16 percent of international patent applications are filed by women inventors. At this rate, the WIPO doesn't expect to achieve gender parity before 2064. That's almost 40 years into the future. So, while progress is being made, clearly much more must be done to quickly close this gap as well as a similar gap in career opportunities for minorities.    Tarianna Stewart – our featured guest in the latest episode of the Ideas to Innovation Season 2 podcast from Clarivate – ventured into her IP career by accident. “I happened to learn about IP during my Ph.D. program and thought, ‘this seems interesting… maybe a little bit better than working in the lab.'” Now an experienced biomedical scientist and accomplished IP professional at the technology unit of New York University in New York City, Tarianna has smart advice for women and people of color who seek to follow in her footsteps and pursue careers in IP and innovation. In our podcast discussion, she recalls how she “fell in love with the tech transfer space,” and offers a ‘been-there-done-that' perspective on what she believes it will take to foster a more inclusive IP and innovation landscape for the benefit of all involved. 

In today's episode, we're talking with Jonathan Adams, Chief Scientist, Institute of Scientific Information, a part of Clarivate.  Jonathan is interviewed by Matthew Ismail, a Conference Director and Editor in Chief of the Charleston Briefings. Jonathan Adams is a jack of all trades in the scholarly communication field. He is a scientist who taught in higher education and published a successful book in the field of biology. He has been an Assistant Secretary and Science Policy Advisor to the UK government. He has founded a startup related to his research and teaching. He has been in charge of research evaluation at Digital Science and Thomson Reuters. And now he is Chief Scientist at ISI with Clarivate Analytics. He is very well qualified to discuss the research landscape! In this podcast, Jonathan and Matthew discuss the recent report published by ISI, U.S. Research Trends:  The Impact Of Globalization and Collaboration. This report discusses many interesting topics, but perhaps the most relevant finding is that US STEM research, while still strong, is no longer dominant in the world. Jonathan and Matthew discuss the factors that have made the US less competitive in STEM research. Social Media: LinkedIn: https://www.linkedin.com/in/matthew-ismail-1a6282a/ https://www.linkedin.com/in/jonathan-adams-5a02188b/ Keywords: #Clarivate, #WebofScience, #data, #DataScientists, #Innovation, #technology, #learning, #education, #knowledge #research, #collaboration, #libraries, #librarianship, #LibraryNeeds, #LibraryLove, #AcademicPublishing, #ScholarlyPublishing, #publishing, #podcasts

In der heutigen XXL-Folge „Alles auf Aktien“ sprechen der Tech-Investor Pip Klöckner und Finanzjournalist Holger Zschäpitz über reiche Norweger dank Aktien, Zinsangst an den Märkten, den weltweit etwas abebbenden Tourismusboom und Wachstumssorgen beim angesagten Sneaker-Haus On Holding. Außerdem geht es um JPM Chase, Bank of America, Norwegischer Staatsfonds, Encavis, SMA Solar, HomeToGo, Sea Ltd, Jumia, PayPal, Clarivate, Seadrill, Constellation Brands, NuStar Energy, Phillips 66, Position Pinterest, On Holding, Nvidia, Marvell, Super Micro Computer, Google, Meta, Adobe, Microsoft, Palantir, C3.AI, IBM, Xtrackers Artificial Intelligence (WKN: A2JAV15). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Guests Karen Carey, BioWorld's managing editor, and Mike Ward, Clarivate's global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit.

Recorded on 07/26/23 Over the last decade, data and analytics have become increasingly engrained in the healthcare system. Given the evolving landscape, we wanted to provide a deeper look into the different types of healthcare data currently available, as well as the users and use cases. This podcast is intended to be the first in a series on healthcare data, and in this episode we provide a general overview of how healthcare data is currently being used, with subsequent podcasts exploring subsets of healthcare data in more depth. To discuss this topic, we are joined by Paul Reuscher. After spending the early part of his career in academia researching health economic outcomes, Mr. Reuscher eventually joined IMS Health, now a part of IQVIA, first as a product manager then eventually helping develop what is now IQVIA's anonymized patient data solution. He subsequently led a similar development program for DRG, which is now a part of Clarivate. Paul currently is Vice President of Clinical Data Products at Forian, a healthcare data intelligence company. For Disclosures, click here bit.ly/3cPHkNW

Growth: it's a mindset.In this episode of the Sales Code Leadership Podcast, Kevin chats with the delightful Leigh Ashton, founder and CEO of Sales Consultancy, about exploring the power of growth mindsets and their profound impact on revolutionizing your sales approach.Leigh shares with Kevin that although high-performing A-players are undoubtedly valuable, fostering a growth culture and uplifting the non-A players within your team can remarkably benefit your organization.Prepare to be inspired as the link between mindset and behavior is unveiled, demonstrating how adopting the right mentality can drive exceptional results. Drawing on her extensive expertise, Leigh also offers invaluable advice for leaders, empowering them to foster progress and development within their teams. Leigh Ashton is the author of two books, a speaker, trainer and coach...and the founder of The Sales Consultancy.She works with Sales Leaders and teams to develop Sales Growth Mindset and healthy sales growth cultures that support personal development, mental well-being and sales success.Her programmes develop Sales Leaders teams to think and perform at a higher level and her clients include NatWest, Wright Medical, AVEVA, Motorpoint, British Airways, Stryker, Headspace, Siemens, Clarivate, Oracle…and more.She's known for increasing sales...and leaving people feeling confident, motivated and inspired to go beyond their comfort zone to achieve greater sales and leadership success!Connect with Leigh: https://www.linkedin.com/in/leighashton1/The podcast is brought to you by Sales Code, helping revenue leaders unlock added value in B2B SaaS sales teams. Your views on our podcast are always welcome, as well as any questions you might have for our podcast guests.Connect with host Kevin Thiele here.

A person born this year is expected to live about 73 years, according to the World Health Organization. But 73 doesn't reveal the full picture. According to a WHO report published in May, advances in science, related technologies and other factors have helped increase life expectancy worldwide by six years between 2000 and 2019.  Good news, right? However, it's also true that 80 percent of premature deaths could be avoided if patients and healthcare professionals had the right information at the right time to make better decisions. That's where artificial intelligence comes in. Today, Patient Connect, a biopharma intelligence company that's part of Clarivate, is integrating AI into clinical software at point of care for patients around the world, such as, for example, the two million people in the U.S. who suffer from heart failure. These new AI tools are enabling more than a million physicians to provide better care for those suffering from a wide variety of diseases by identifying the most at-risk patients or the patients with the most unmet needs.     To explain how such sophisticated solutions provide better and best care for patients, we welcome back Dr. Grace Lomax to the “Ideas to Innovation Season 2” podcast from Clarivate. Grace founded Patient Connect with her sister, Zoe Barker, in 2008, and the company was acquired by Clarivate in 2021. Patient Connect engagement solutions improve patient outcomes by delivering clinical messaging to the workflows of physicians and pharmacists at the point of patient contact. This messaging helps guide patients to better understand their treatment and disease and empower them to make informed healthcare decisions.     For more information on the many ways Clarivate is using AI to deliver the highest quality content and insights to customers, go to www.clarivate/ai 

Among the consequences of COVID-19 is its adverse impact on the mental health and wellbeing among university students in the United States.  Today's students deal with many challenges from coursework, relationships and adjustments to campus life, to economic strain, social injustice, mass violence and various forms of loss related to the pandemic. In a 2021 survey, nearly 75 percent of college presidents listed students' mental health as their most pressing issue. And key findings from a report released this year by non-profit Mental Health America shows more than 10 percent of young people are experiencing depression that severely impairs their ability to function at school or work, at home, with family or in their social life.  Many school leaders have started to think outside the box about how to help. They're finding ways to incorporate a broader culture of wellness into their policies, systems and day-to-day campus life. In this episode of “Ideas to Innovation Season 2” from Clarivate, we speak with Lisa O'Donnell, assistant professor for the department of social work at Wayne State University in Detroit, Michigan. An expert in bipolar disorder and severe mental illness, she brings a compelling perspective to the topic of university students and mental health. Lisa has served as a clinician for the state of Michigan for more than 18 years, primarily working with adults who have severe mental illness as well as anxiety disorders and OCD-related disorders.   For information on subscriptions to mental health e-books from ProQuest, part of Clarivate, go to https://bit.ly/proquestmentalhealth 

Audio from the 2022 Charleston Conference from a Neopolitan Session titled “Whole EBook ILL Redux.” In this session, panelists discussed results and updates on ProQuest's, a part of Clarivate,  successful Whole Ebook ILL pilot. This session was presented by Allen Jones (the New School), Whitney Murphy (ProQuest), George Machovec (Colorado Alliance of Research Libraries) , Sylvia Bonadio (Brill), and Lisa Nachtigall (Oxford University Press).  Video of the presentation available at: https://youtu.be/5-XQUXZGia4 Social Media: https://www.linkedin.com/in/ajones3066/ https://www.linkedin.com/in/wkmurphy/ https://www.linkedin.com/in/george-machovec-3a649a4/ https://www.linkedin.com/in/sylviabonadio/ https://www.linkedin.com/in/lisanachtigall/  Keywords: #LibraryResources, #eresources, #ebooks, #ebookLending, #interlibrarylending, #ProQuest, #EbookCentral,  #pilotproject, #technology, #innovation, #collaboration,#engagement, #problemsolvers, #libraries, #librarians, #information, #ChsConf,  #LibrariesAndVendors, #LibrariesAndPublishers, #libraryissues, #libraryneeds,#librarylove, #librarychallenges, #libraryconference #podcast  

Every year, Clarivate publishes a list of the Top 100 Global Innovators, companies and organizations that sit at the very top of the global innovation ecosystem, with the most consistent over-the-bar performance in innovation. Since the list began in 2012, only 19 companies can claim the distinction of being recognized continuously, year after year. One such company is 3M – the iconic global manufacturer and distributor well known for its cutting-edge scientific research and invention of groundbreaking products such as Post-it ® Notes, Scotchgard ™ Fabric Protector, and Thinsulate™ Insulation. In our latest episode of Ideas to Innovation Season 2, we'll learn how 3M is constantly pushing the boundaries of what's possible with science and innovation, where the power of science and the spark of human ingenuity come together in perfect harmony.    Read more - https://clarivate.com/podcasts/ideas-to-innovation-season-two/  

In February 2023, we celebrated women in science around the world for their significant contributions to science, technology, engineering and mathematics, collectively known as STEM.   In this episode we discuss the achievements and challenges for women in science and for girls who are thinking about careers in STEM fields with Dr. Rachel Webster, Director, Healthcare Research and Data Analysis, Oncology and Biosimilars at Clarivate.  Read more - https://clarivate.com/podcasts/ideas-to-innovation-season-two/  

Through its Citation Laureates program, Clarivate recognises individuals whose research publications are highly cited and whose contributions to their fields have been extremely influential, even transformative. This year, we named twenty world-class researchers from four countries as Citation Laureates. These are researchers whose work is deemed to be ‘of Nobel class', as demonstrated by analysis carried out by the ISI, and who are in the running for future Nobel honours. In this episode, you'll hear from two of this year's Citation Laureates who share insights into their work, how they got started, tips for young researchers, and more - Mary-Claire King, Professor of Medicine and of Genome Sciences, School of Medicine, at the University of Washington in Seattle, in the United States, recognized for demonstrating inherited susceptibility for breast and ovarian cancer and discovering the role played by mutations of the BRCA1 gene and Zhenan Bao, the K.K. Lee Professor of Chemical Engineering, and Director, Stanford Wearable Electronics Initiative (eWEAR), at Stanford University, California, recognized for the development of novel biomimetic applications of organic and polymeric electronic materials, including flexible ‘electronic skin.' Hosted on Acast. See acast.com/privacy for more information.

Audio from the 2021 Charleston Library Conference from a session titled “State of The Academic Library: Library Leaders Share What Makes Institutions Thrive” presented by Elijah Scott, Executive Director, Library Services, Florida Virtual Campus; Kathleen Bauer, Director, Collections, Discovery and Access Services, Trinity College; Kate McCready, Interim AUL for Collections & Content Strategy, University of Minnesota Libraries; Alison Roth, Marketing Communications Manager, ProQuest, Part of Clarivate; and moderated by Katy Aronoff, Senior Director, Solutions Architecture, Ex Libris/ProQuest, Part of Clarivate. How does your academic library compare to your peer libraries across North America? What are the emerging trends in today's academic libraries and what are institutions doing to prepare for tomorrow?  Each year, the Academic Libraries Benchmark Survey – administered by Library Journal and commissioned by Ex Libris – asks academic libraries about the core foundations of what makes an academic library thrive. This survey is well-known for measuring the academic library's needs, challenges, its place in the university ecosystem, and what next steps are most important to help it flourish. With all the changes in higher education over the past year, this data has become more essential than ever. The 2021 survey results are shared with us in this lively panel discussion. Leaders in the library community will provide their reactions to the results of this valuable research. Video of the presentation available at: https://youtu.be/UhmfRJCLgWg Social Media: https://www.linkedin.com/in/elijah-scott-7596996/ https://www.linkedin.com/in/kathleenfbauer/ https://www.linkedin.com/in/kate-mccready-2a61624/ https://www.linkedin.com/in/alison-roth-a098833/ https://www.linkedin.com/in/karonoff/ Twitter: @ProQuest  @ExLibrisGroup @Clarivate

Today, with so much information available online, verification of information – who created it and who shared it – has become part of standard operating procedures in many enterprises to create a climate of trust surrounding information that can be used and acted upon. Nowhere is this truer than in the field of scientific research and reporting. In this episode, Nandita Quaderi, editor-in-chief for the Web of Science™ at Clarivate, shares her views on the topic of research integrity. She describes the importance of conducting and presenting research in a way that allows others to have trust and confidence in the methods used. And she warns of the dangers that occur in instances when the scholarly record cannot be trusted. Hosted on Acast. See acast.com/privacy for more information.

Join us for our latest podcast episode featuring a conversation between Nandita Quaderi, the Web of Science, and Matthew Ismail, Editor in Chief of the Charleston Briefings, and a Conference Director at the Charleston Conference. Nandita Quaderi is Editor-in-Chief and Editorial VP, the Web of Science. In this podcast, Nandita and Matthew discuss Web of Science and the upcoming changes to how Clarivate will assign journal impact factors for scholarly publications. Nandita provides some helpful background explanations about impact factors and Web of Science for the non-specialist and tells us how Clarivate prefers impact factors to be used in the world of scholarly communication. Nandita then discusses Clarivate's upcoming plan to assign impact factors to the Emerging Sources Citation Index and the Arts and Humanities Citation Index and what this means for the impact factor in the near future. Social Media: LinkedIn: https://www.linkedin.com/in/nanditaquaderi/ https://www.linkedin.com/company/clarivate/ https://www.linkedin.com/in/matthew-ismail-1a6282a/  Twitter: @Clarivate Keywords: #Clarivate, #WOS, #webofscience, #researchers, #publishing, #scholarlypublishing, #impactfactor, #openaccess, #universal, #OA, #digital, #libraries #librarianship  #scholarlyresearch, #scholarlycommunication, #podcasts 

The healthcare industry worldwide is changing. Hospitals and healthcare systems in many countries are struggling to control costs, increase revenues, train and retain skilled employees, and treat and care for patients. In the business of health care, new approaches and ideas are coming to the fore as part of this journey to transform healthcare and ultimately change patients' lives. In this episode, podcast host Neville Hobson joins guests Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, and Jerry Harrison, Rock and Roll Hall of Fame inductee as a member of Talking Heads, and healthcare and life sciences business entrepreneur, to discuss new approaches to investment that connect financial and human capital to communities in the healthcare space that share knowledge, interest and passion for healthcare innovation. And we examine how innovation is bringing some startling ideas in healthcare to life. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Today we continue our discussion in part two about the relationship between our stuff and our personal identities with Dr. Sam Gosling. Sam Gosling is a Professor of Psychology at the University of Texas, Austin. He did his doctoral work at the University of California at Berkeley, where his dissertation focused on personality in spotted hyenas. His current research focuses on the psychology of physical space, how personality is expressed in everyday contexts in daily life, and in new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in the contexts of their natural habitats. He is an elected fellow of the Association for Psychological Science and Society for Personality and Social Psychology (or SPSP for short). Dr. Gosling is the recipient of the American Psychological Association's Distinguished Scientific Award for Early Career Contribution, the Carol and Ed Diener Award in Personality Psychology, and SPSP's award for methodological innovation. His book, “Snoop: What your stuff says about you” which we'll also discuss, is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate, which is global leader in providing trusted insights and analytics, have identified him as one of the most highly cited scientists in the world. SOURCES: https://docs.google.com/document/d/1VbPjsPW26ZUte4wkH9h3s2TmcBHPOp_yTBgVq3C2AHk/edit?usp=sharing MUSIC: "Sun Shines Through the Leaves" --- ©2022 Britton Rice, Ben Santoriello

Today we're talking about the relationship between our stuff and our personal identities with Dr. Sam Gosling. Sam Gosling is a Professor of Psychology at the University of Texas, Austin. He did his doctoral work at the University of California at Berkeley, where his dissertation focused on personality in spotted hyenas. His current research focuses on the psychology of physical space, how personality is expressed in everyday contexts in daily life, and in new methods for collecting data in the behavioral sciences. His approach is ecological, emphasizing the importance of studying individuals in the contexts of their natural habitats. He is an elected fellow of the Association for Psychological Science and Society for Personality and Social Psychology (or SPSP for short). Dr. Gosling is the recipient of the American Psychological Association's Distinguished Scientific Award for Early Career Contribution, the Carol and Ed Diener Award in Personality Psychology, and SPSP's award for methodological innovation. His book, “Snoop: What your stuff says about you” which we'll also discuss, is based on the idea that we deliberately and inadvertently express our personalities in the environments in which we live and work. Clarivate, which is global leader in providing trusted insights and analytics, have identified him as one of the most highly cited scientists in the world. SOURCES: https://docs.google.com/document/d/1VbPjsPW26ZUte4wkH9h3s2TmcBHPOp_yTBgVq3C2AHk/edit?usp=sharing MUSIC: "Sun Shines Through the Leaves" _____ ©2022 Britton Rice, Ben Santoriello

This week we're diving into the OCLC lawsuit against Clarivate for its MetaDoor product, the implications of Roe being overturned, and ALAmageddon.  Becky Yoose (@yo_bj) / Twitter  Managing Data for Patron Privacy: Comprehensive Strategies for Libraries | ALA Store  About Us - LDH Consulting Services    Media mentioned Privacy Guides  https://gavialib.com/2022/06/stoning-goliath/ Library Loon article.  Karen Coyle - https://kcoyle.blogspot.com/2022/06/the-oclc-v-clarivate-dilemma.html  OCLC's non-profit status « The Thingology Blog Outsourcing the catalog department: A meditation inspired by the business and library literature - ScienceDirect SkyRiver vs. OCLC antitrust lawsuit – librarian.net

Audio from the 2022 Charleston In Between virtual conference from a session titled "The Mergers & Acquisitions Landscape in Scholarly Publishing” moderated by by Roger Schonfeld, Director, Libraries & Scholarly Communication & Museums, Ithaka S+R and featuring Christopher Burghardt, Senior Vice President, Academia and Government, Clarivate, and Ofer Mosseri, Senior Vice President and General Manager, Ex Libris. Roger, Christopher and Ofer discuss the Clarivate/ProQuest Acquisition, and give a recap and overview designed to capture the highlights, downstream consequences, open questions, and updates since our last Charleston In Between session. Video of the presentation available at:  https://youtu.be/8UyYtd1rZzU Social Media: https://www.linkedin.com/in/rogerschonfeld/ https://www.linkedin.com/in/christopher-burghardt-a3509321/ https://www.linkedin.com/in/ofermo/ Twitter: @rschon  @Clarivate

Every year, nearly 41 million people worldwide die prematurely from non-communicable diseases. Yet 80% of premature deaths could be avoided if patients and healthcare professionals alike had the right information at the right time to make better decisions.In this podcast Dr. Grace Lomax, the Clinical Director at Patient Connect, a part of Clarivate, shares her experience as a physician highlighting numerous unmet needs beyond just clinical issues – especially around healthcare literacy and education at the point of care. See acast.com/privacy for privacy and opt-out information.

For more than a decade, Ukraine has been a valuable part of scientific research with over 52,000 papers, many highly cited, written by Ukrainian researchers. This essential work came to a halt when Russia invaded Ukraine in February 2022. In this podcast Gali Halevi, Director at the Institute for Scientific Information at Clarivate, shares her perspectives on the impact on scientific research and discovery and how Clarivate is supporting displaced researchers in Ukraine. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Grace Lomax, Clinical Director at Patient Connect, a part of Clarivate. Grace's experience as a physician highlighted numerous unmet needs beyond just clinical issues – especially around healthcare literacy, education at the point of care, adherence and more. She discusses how Patient Connect uses technology and communication strategies to inform and support patients at the point of care, and shares examples of campaigns that improved outcomes in cancer, hypertension, rare disease and asthma. See acast.com/privacy for privacy and opt-out information.

Today's episode is from the 2021 Charleston Library Conference from a session titled "Whole Ebook ILL: On the Road Toward a Scalable Solution” presented by Whitney Murphy, Sr. Product Manager, Clarivate; Allen Jones, Director, Digital Library and Technical Services, The New School; George Machovec, Executive Director, Colorado Alliance; Sylvia Bonadio, Sales Director, Americas, Brill; and Lisa Nachtigall, Director, Global Institutional Resellers and Channel Strategy, Oxford University Press. Interlibrary loan (ILL) has a long and valued history, and today, it's more important than ever. Stagnant library budgets and increasing virtual learning environments, combined with the impact of the global pandemic, all increased the importance of borrowing and lending across libraries. While ILL services have expanded to include support for digital lending, a scalable solution does not yet exist for aggregated whole ebook lending. Supporting a shift to whole ebook lending offers an opportunity for publishers and libraries to collaborate on how best to address challenges and leverage the affordances of digital content and workflows. Join this discussion to hear from both academic librarians and publishers as they discuss the benefits and concerns surrounding ILL models and the opportunities presented by whole ebook lending. Early results and findings from a successful whole ebook ILL pilot will be shared. Video of the presentation available at:  https://youtu.be/m0NRlxJElrM Social Media: https://www.linkedin.com/in/wkmurphy/ https://www.linkedin.com/in/ajones3066/ https://www.linkedin.com/in/george-machovec-3a649a4/ https://www.linkedin.com/in/sylviabonadio/ https://www.linkedin.com/in/lisanachtigall/ https://www.linkedin.com/school/the-new-school/

In today's episode, we look at the state of the global innovation landscape and the direction of ideas still to come, as revealed by Top 100 Global Innovators 2022 from Clarivate – an annual list that recognizes the organizations that demonstrate consistent, above-the-bar innovation excellence and which sit at the very top of the global innovation ecosystem. Joining us are Davy Brown, Vice President and Chief Technology Officer of Industrial Solutions for TE Connectivity and Ed White, Chief Analyst and Vice President of IP and Innovation Research, at Clarivate. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Matthew Arnold, Principal Analyst at Clarivate speaks with Dr. Kenton Johnston, Associate Professor of Health Management and Policy at Saint Louis University about disparities in the US health system. Matthew and Ken discuss both the historical context as well as the evolution of the system since the establishment of the Affordable Care Act, and how the entire spectrum of the healthcare system can work to address social determinants of health. Learn more in the full episode. See acast.com/privacy for privacy and opt-out information.

Clarivate recently unveiled its annual list of Highly Cited Researchers, the “who's who” of the world's influential scientists and social scientists. The list from the Institute for Scientific Information recognizes some 6,600 researchers for demonstrating significant influence among their peers, as evidenced by the production of multiple highly cited papers that rank in the top 1% by citations for field and year, as indexed in the Web of Science over the last decade. Joining us today are David Pendlebury, Head of Research Analysis at the Institute for Scientific Information; Professor Liu Bin, Vice President of Research and Technology at the National University of Singapore; and Dr. Robin Drennan, Director of Research and Innovation at the University of the Witwatersrand, Johannesburg in South Africa. See acast.com/privacy for privacy and opt-out information.

Two years into a global pandemic, innovation, at speed, continues unabated. Collaboration across borders remains strong, thanks to technological advancements in connectivity and mobile communications. Social interaction is evolving, as the physical and virtual world collide with the rise of the metaverse. Expertise at a distance, including remote medicine, is becoming more pervasive. Sustainability sits at the core of the agenda for businesses, government and society.As the world continues its tentative recovery, what does 2022 and beyond hold for us? Joining us today are Zaid Al-Nassir, Principal Analyst for Medical Technology, Lin Wang, Portfolio Marketing Manager, and Arun Hill, Principal Consultant, all from Clarivate. See acast.com/privacy for privacy and opt-out information.

In this episode we introduce the podcast, break down the Proquest acquisition by Clarivate, and talk about the differences between a non-profit and profit when it comes to resources.

What is the common ground for modern psychotherapy? - Professor Stefan G. Hoffman, Professor Jacques P. Barber, Professor Paul Salkovskis, Professor Bruce E. Wampold https://english.swps.pl/eaclipt The field of psychotherapy has developed from different roots, and many clinicians and scientists still consider psychotherapy as a collection of unconnected groups of theories and associated interventions. This approach prevents a cohesive development of the discipline and a holistic treatment of patients. During the webinar, Professor Stefan G. Hofmann from the Philipps-University Marburg, Germany and Boston University, USA will talk about process-based psychotherapy, which takes the view that mental health problems are assumed to exist as systems of inter-connected elements. The keynote lecture will be followed by a panel discussion on finding the common ground for evidence-based psychotherapies. KEYNOTE LECTURE: PROCESS-BASED PSYCHOTHERAPY For decades, evidence-based therapy, such as Cognitive Behavioral Therapy (CBT), has been defined in terms of treatment protocols focused on syndromes as defined by the DSM and ICD. These psychiatric classification systems assume that psychological problems are expressions of latent disease entities. However, there is little evidence to support this restrictive assumption. A process-focused approach (Process-Based Therapy, PBT) is now emerging. This approach does not rely on the assumption that psychological problems are expressions of latent disease entities, but it does not rule it out either. Instead, mental health problems are assumed to exist as systems of inter-connected elements. As is true for many complex networks, such a change can occur abruptly once the network reaches a tipping point. PBT directly links treatment techniques to processes in the individual client, thereby linking classification to treatment based on functional analysis and complex networks. This offers a less restrictive and more externally valid alternative to the latent disease model, while offering exciting new directions for future research in psychiatry and is in line with personalized medicine. KEYNOTE SPEAKER Stefan G. Hofmann, Ph.D. – is the Alexander von Humboldt Professor of Clinical Translational Psychology of the Philipps-University Marburg, Germany, and also Professor of Psychology at the Department of Psychological and Brain Sciences at Boston University. He has been president of ABCT and IACP, and is editor-in-chief of Cognitive Therapy and Research. He has published more than 400 peer-reviewed journal articles and 20 books. He has been included in list of a Highly Cited Researcher by Clarivate and Thomson Reuters since 2015, among many other awards, including the Aaron T. Beck Award for Significant and Enduring Contributions to the Field of Cognitive Therapy by the Academy of Cognitive Therapy. His research focuses on the mechanism of treatment change, translating discoveries from neuroscience into clinical applications, emotion regulation, and cultural expressions of psychopathology. For more information, see: www.bostonanxiety.org. PANEL DISCUSSION Is psychotherapy just a collection of different approaches? Searching for the common ground for evidence-based psychotherapies

Clarivate recently unveiled its annual list of Highly Cited Researchers, the “who's who” of the world's influential scientists and social scientists. The list from the Institute for Scientific Information recognizes some 6,600 researchers for demonstrating significant influence among their peers, as evidenced by the production of multiple highly cited papers that rank in the top 1% by citations for field and year, as indexed in the Web of Science over the last decade. An outstanding faculty is the lifeblood of every notable research institution, and this year Highly Cited Researchers are based at more than 1,300 institutions all over the world. In this episode we speak to representatives from some of these universities, hospitals, research institutions, laboratories and government organizations about how they excel in a competitive global environment – supporting their Highly Cited Researchers in a way that encourages collaboration, facilitates career growth and accelerates highly innovative research. See acast.com/privacy for privacy and opt-out information.

The increasing use of artificial intelligence (AI) technologies across all stages of drug development is presenting interesting new challenges around the world. One key question of growing importance: Can an AI algorithm be an inventor? If so, can the AI system apply for or receive a patent? We spoke to Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project and Jim Belfiore, senior vice president of innovation at Clarivate, to learn more about the implications of these questions and how patent offices and courts are handling them so far. What's at stake in recognizing a more prominent role for AI in the innovation sphere? Could AI inventorship potentially create IP asset inflation? Listen to find out. See acast.com/privacy for privacy and opt-out information.

Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, discusses PharmExec's 2022 pipeline report, which appears in our December issue. Mike goes behind the numbers and provides some interesting insights from the report provided by Clarivate.

It has been a decade since the Clarivate Top 100 Global Innovators was conceived. Every year, for the last decade, Clarivate has honored the companies and institutions across the world that represent innovation at its finest.Today, we welcome guests from two of this year's Top 100 Global Innovators to talk about creating and sustaining an innovative company through fast changing and challenging times. We also talk about the sustainability agenda, how it must work hand in hand with, not just the cycle of innovation, but indeed, be an integral part of companies' fabric if we are to secure a livable and resilient world, today and for generations to come. See acast.com/privacy for privacy and opt-out information.

Marilyn Johnson is Senior Director Sustainability at Clarivate and was recently named by The American Energy Society as one of the top 500 Global Sustainability Thought Leaders.Marilyn and her work are great examples of how DEI is increasingly influencing thought and action in other functions across the organization.  While the impact of DEI is perhaps most obvious in HR related areas such as Talent Management or Employee Wellbeing,  Marilyn explains how it has become a core principle guiding sustainability at Clarivate.Sustainability and Diversity both share a common characteristic - to be effective they can't be a function bolted on to the organization, they have to inform all activities in the organization.  They are thus natural partners in organizational transformation and culture.This is a thought provoking, stimulating conversation that invites listeners to think more expansively about DEI to drive lasting change.

In this episode of Conversations in Healthcare, Mike Ward speaks with Oriol Serra, former Head of Site Intelligence and Selection at Pfizer and Simon Andrews, Vice President of RWD Engagements and Innovations at Clarivate about optimizing patient-first clinical trial design and ensuring trial groups align to real-life populations and needs. The group discusses the ins and outs to bring clinical trial management in-house, how to modernize trial designs with emerging data and intelligence, overcoming key challenges and advice for other pharma and biotechs looking to go down this path. Learn more in the full episode. See acast.com/privacy for privacy and opt-out information.

Actors have their Oscars, and researchers have their Nobels. The Nobel prize has been the global pinnacle symbol of achievement in science since 1901 and economics since 1969. Each year since 2002, the Institute for Scientific Information (ISI)™ at Clarivate has identified a small group of Citation Laureates™: exceptionally highly cited scientists and economists whose influence is comparable to past and future Nobel prize winners. So far, 64 Citation Laureates have gone on to win a Nobel Prize, including five this year in 2021. Joining us are David Pendlebury, Head of Research Analysis at the Institute for Scientific Information, and David Audretsch, Distinguished Professor and Ameritech Chair of Economic Development with the O'Neill School of Public and Environmental Affairs at Indiana University, who has recently been named a Citation Laureate for 2021. Together we explore what it takes to win a Nobel Prize, and how Clarivate uses both quantitative and qualitative analysis to predict Nobel success, often years before a Nobel Prize is given. We discuss the fundamental role that citations play in identifying these giants of research, and how it feels to join the ranks of other ‘Nobel-class' researchers in the Hall of Citation Laureates. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward speaks with Carolyn Hynes, Director of Regulatory Intelligence at AstraZeneca, and Céline Rodier, Senior Health Policy Manager at Clarivate, about strategies and tools to gather and assess regulatory intelligence, as well as KPIs and approaches to demonstrating ROI within your organization. Get actionable takeaways in the full episode. See acast.com/privacy for privacy and opt-out information.

COVID-19 is an enormous global challenge that has required an unprecedented level of engagement by stakeholders within pharma, research and policy. While SARS-CoV-2 emerged as a novel virus to which humans had no immunity, infection control measures have been deployed and existing as well as new and emerging technologies are being leveraged to speed the development of new treatments and therapies. Clarivate partnered with pharma in an international effort to bring life-saving vaccines to market.Joining us in this new episode of Ideas to Innovation are Clarivate experts Danielle Waterman, Senior Quality Specialist, Lynn Yoffee, Publisher BioWorld, and Kevin Yin, Senior Analyst – Medtech Insights, to provide a snapshot of key milestones over the past year and share their perspectives on what is to come. They discuss key medical responses to the pandemic, what the “new normal” looks like and offer analysis and a review of the latest data and insights that can provide a complete view of the healthcare landscape. See acast.com/privacy for privacy and opt-out information.

Chris currently directs the operational and strategic proposal center at Clarivate, a global provider of Scientific and Intellectual Property solutions. The team works within the commercial operations division to manage hundreds of complex proposals each year across all geographies, as well as maintaining opportunity pipeline and proposal automation/content curation processes.Chris is APMP professional qualified (2015) and has previously sat on the UK APMP board as founding director of Technology. At Clarivate, he has been shortlisted for the Sales Partner of the Year award (2016), Deal of the Year award (2016) and multiple APMP UK Awards (including Leadership and Knowledge Management as well as additional nominations from within his team). Chris has been accepted as an APMP UK mentor in 2021, as well as previously mentoring practitioner candidates to successful passes. Chris is finalizing an undergraduate degree at the Open University in the UK in Psychology, and hopes to progress into Doctoral research, exploring the Psychology of the bids and tenders market from 2022.In his spare time, Chris enjoys spending time with his family – especially at the movies, growing at the family allotment and training together in Taekwondo. He studies and is an avid runner, having recently completed a 100Km ultramarathon in London (with more booked for 2022). He loves camping, and is an active volunteer for local community ventures such as Greenslate community farm in Wigan.

Over the past decade, Clarivate has identified the Top 100 Global Innovators, the companies and institutions at the pinnacle of the global innovation landscape that have contributed new ideas, solved some of the world's most complex challenges and created new value.Today, we have a guest speaker from Thales, one of those 100 companies join us to talk about how businesses today go about creating and sustaining an innovative company, the complexity of modern-day innovation and how it continues to fascinate and inspire. Our guest speaker is Bernhard Quendt, Chief Technical Officer and Senior Vice President at Thales joining Ed White, Head of Analytics, IP Group at Clarivate. See acast.com/privacy for privacy and opt-out information.

In a new report from Clarivate, The road ahead: sustainable vehicles today and in the future, we look at the fascinating history of the electric vehicles, the innovation spark that finally fueled its mass market production and wider consumer acceptance, and the state of innovation in the electric vehicles sector today.Today, we have subject matter experts from Clarivate talking about the new report and the electric vehicles which count among the handful of modern-day inventions that have truly captured our imagination.Our speakers today are Ed White, Head of Analytics, Robert Reading, Director of Government and Content Strategy, Brian King, Head of Policy and Advocacy and David Marques, Principal Consultant, Litigation Products & Strategy. See acast.com/privacy for privacy and opt-out information.

In this week's episode of the ‘V-POD'- IIMV Podcast series, we are glad to welcome Mr Puneet Jain. Currently serving as the Vice President of Clarivate, Mr Jain has a massive experience of over two decades in setting up and scaling Global Development Centres (GDC) for various fortune 500 companies. Throughout his career, he has taken projects in India and countries like Russia, Italy, Poland, and the USA. He has prospered in the roles of Country Head at IHS Markit and as Associate Director at Applied Materials India. He has worked closely with the US Consulate and US Department of Commerce while fulfilling the role of Chairman of the Indo-American Chamber of Commerce, promoting several bilateral trades and initiatives. Mr Jain aided MSME in adopting IT services while being Confederation of Indian Industry's (CII) State Council Member and IT panel member.

In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Toby Richardson, who is Head of Business Development and Licensing; Deputy Director of Business and Innovation at The Institute of Cancer Research. Mike and Toby discuss how research collaborations between the ICR and biopharma companies help the Institute achieve its mission to make the discoveries that defeat cancer. Learn more in the full episode. See acast.com/privacy for privacy and opt-out information.

We talk with Jasper Simons, Chief Publishing Officer at the American Psychological Association (APA), about how trends shift in the psychology industry, and what psychedelic medicine needs for adoption.Highlights— The Nugget: psychedelic federal legislation proposal (0:44)— The Noodle: is it time to stop using the words "trip" & "psychedelics" (1:25)— What's needed to shift the paradigm of psychedelics within psychology (2:40)— Biggest roadblock to innovation in psychology (7:11)— The need for legality and reimbursement (7:50)— Psychology as a science with humans as the observer and the observed (10:40)— Challenge of having conversations all go back to COVID (12:15) — Engaging with undergrads and reimagining education (14:45)— Personal career strategy as an executive (17:45)— Advice to a 25-year old aspiring executive for the quarter life crisis (21:45)— How Jasper deals with adversity and change (26:55)— How therapists view psychedelics (28:55)— A Soul Search with Jasper (31:25)— The one musical band he'd bring with him to a desert island— Clap and a Slap {Double Blind and Compass Pathways} (34:25)Jasper SimonsJasper Simons is an information industry executive with more than 20 years of experience in building and growing products, platforms, and content portfolios for leading knowledge businesses.  Simons is the Chief Publishing Officer at the APA, overseeing the world's premier portfolio of journals, books and digital solutions for behavioral scientists, health practitioners, educators and the public.Prior to joining the APA, Simons was a Vice President of Product and Market Strategy at Thomson Reuters (now Clarivate). There he managed software solutions for publishers and associations, including ScholarOne Manuscripts, the leading content management platform for the industry. Simons currently serves on the Board of Directors of Crossref, a not-for-profit membership organization that exists to make scholarly communications better. He also serves on the board of the Association of American Publishers (AAP), which represents the leading book, journal, and education publishers in the United States on matters of law and policy. Simons earned an MA in Political Science & Sociology from the University of Amsterdam and a BSc in Management & Organization from Van Hall Larenstein College. Find Jasper here:https://www.linkedin.com/in/jaspersimons1/ --www.textpert.ai 

In a new report from Clarivate, The road ahead: sustainable vehicles today and in the future, we look at the fascinating history of the electric vehicles, the innovation spark that finally fueled its mass market production and wider consumer acceptance, and the state of innovation in the electric vehicles sector today.Today, we have subject matter experts from Clarivate talking about the new report and the electric vehicles which count among the handful of modern-day inventions that have truly captured our imagination. Our speakers today are Ed White, Head of Analytics, Robert Reading, Director of Government and Content Strategy, Brian King, Head of Policy and Advocacy and David Marques, Principal Consultant, Litigation Products & Strategy. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Phil Clare, the Deputy Director, Research Services (Knowledge Exchange and Engagement) at the University of Oxford. Mike and Dr. Clare discuss the key role that university research plays in shaping new medicines and technologies, and what that process looks like. Learn more in the full episode. See acast.com/privacy for privacy and opt-out information.

Clarivate Plc, Q2 2021 Earnings Call, Jul 29, 2021

Every year since 2012, Clarivate identifies the Top 100 Global Innovators. These are companies and institutions at the pinnacle of the global innovation landscape that have contributed new ideas, solved some of the world's most complex challenges and created new value.Today, we have a guest from Boston Scientific, one of those 100 companies and institutions join us to talk about the value of innovation culture, how businesses today go about creating and sustaining an innovative company and embracing the sustainability imperative.Our guest speaker is David Knapp, Vice President of Research and Development for Peripheral Interventions at Boston Scientific joining Ed White, Head of IP Analytics at Clarivate. See acast.com/privacy for privacy and opt-out information.

This week, ATG the Podcast interviews Mitchell Davis, CEO and Founder of BiblioLabs, and Robert Miller, CEO of Lyrasis, about the recent purchase of BiblioLabs by Lyrasis. The interview is conducted by Leah Hinds, Executive Director of the Charleston Hub, and Tom Gilson, Associated Editor of Against the Grain. Topics range from the acquisition, to potential changes in corporate culture, the future of existing projects, how they both see the future of ebooks, and more. Special Announcement The Charleston Conference is planning a very special “In Between” half-day virtual mini-conference event to explore important late-breaking developments that can't wait til November for discussion! Our first panel will cover the Clarivate acquisition of ProQuest, and will be moderated by Roger Schonfeld of Ithaka S+R. The second panel is called “Exiting the Tunnel” and will feature reflections from savvy executives on what the bright lights of a post-Covid world offers to them. We hope you'll join us on July 28 at 10:30 AM EST.  Registration is open now on our website.  Registration Link for "Charleston In Between:"  https://charlestonconference.regfox.com/charleston-in-between Visit Charleston-Hub.com for more info.

For almost 50 years, the global research community has relied on the data in the Journal Citation Reports (JCR)™ to identify the world's leading journals. The JCR is based on data from the Web of Science™, the world's largest publisher-neutral global citation database, and its journal intelligence metrics play a key role for funders, institutions, librarians and researchers. Academic publishers across the globe use the reports to evaluate their journals' impact in their field and promote them to the research community – so each year's update is met with great anticipation. In this episode we welcome guests from the Institute for Scientific Information™ at Clarivate, as well as publishers Hindawi, Frontiers and SAGE Publishing, to talk about the recent 2021 Journal Citation Reports release and the treasure trove of new features inside. Together we'll be exploring the fundamental role the JCR plays in supporting academic research and accelerating the pace of innovation by providing transparent, publisher-neutral journal intelligence and helping those in the research community make better informed, more confident decisions. See acast.com/privacy for privacy and opt-out information.

Special Announcement The Charleston Conference is planning a very special “In Between'' half-day virtual mini-conference event to explore important late-breaking developments that can't wait until November for discussion. It will include a Panel on Clarivate's acquisition of ProQuest and a panel where savvy executives reflect upon what the bright light of post covid offers to them. We hope you'll join us on July 28 at 10:30 AM EST.  Registration is open now on our website.  Registration Link for "Charleston In Between:"  https://charlestonconference.regfox.com/charleston-in-between In today's episode we have an Interview of Anna Abalkina, research fellow, Freie Universität Berlin. The interview was conducted by Matthew Ismail, Editor in chief of the Charleston Briefings and Conference Director at the Charleston Conference.  Anna has recently written an article for the Scholarly Kitchen entitled "Unethical Practices in Research and Publishing-Evidence From Russia."  She has a background in international economics, but recently has turned her focus towards Academic Misconduct, Plagiarism and predatory and hijack journals.  Anna has been an expert at Disernet since its founding in 2013 and she is part of a network of Russian researchers.  She joined because she found her own paper had been plagiarized. When she asked the journal to react, she was unhappy with their response and realized the lack of rights authors can have.  She said there is also wide plagiarism taking place in papers that have been translated from Russian to English and published outside of the Russian context by predatory journals.  The network has certain criteria on what predatory is and the colors and shadows of predatory and dishonest practices. They are trying to create a ranking of Russian journals to predict quality, honesty and fraudulent behavior patterns. She says corruption and potential damage to the Russian economy prevent the government from taking action against violation of ethical principles in the field of scientific publications. She says the threat has been underestimated against academic publishing and academic integrity, and she will continue her work with detection of hijack journals and creating a list of hijack journals that is timely and updated regularly.      

On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer's treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the build up of a protein known as beta amyloid that some think might be one of the possible causes of Alzheimer's disease. While the approval has been applauded by some, it is not without controversy. We will be asking our guests how innovation in the search for treatments of Alzheimer's disease is evolving.Our guest speakers are Mei Mei Hu, Chief Executive Officer at Vaxxinity, Hans J. Moebius, Chief Medical Officer at Athira Pharma, Raymond J Tesi, Chief Executive Officer and Chief Medical Officer at Inmune Bio, as well as Jerre Stead, Executive Chairman and Chief Executive Officer of Clarivate Plc, and Jonathan Searles, Senior Director on the CNS/Ophthalmology therapy team at Clarivate. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Francesco De Rubertis, a co-founder and managing partner at Medicxi, one of the most prominent financial supporters of innovative biotech activity. Francesco provides insights into how the biotech venture capital model has evolved in the past decades to an asset-centric approach, and discusses Centessa, which recently secured $250m in funding. Learn more in the full episode. See acast.com/privacy for privacy and opt-out information.

Clarivate market experts break down the opportunities and potential threats for 2021's Drugs to Watch – the key drugs expected to be blockbusters by 2026. See acast.com/privacy for privacy and opt-out information.

Welcome to the ‘Ideas to Innovation' podcast. In this brand-new series, we'll engage in conversation with experts and industry leaders to discuss innovation at its core. In this episode we have guests from three of the Top 100 Global Innovator companies and institutions join us to talk about the value of innovation culture and how businesses today go about creating and sustaining an innovative company. We will be asking our guests how innovation is helping the world overcome the pandemic and deliver green shoots of recovery.Our guest speakers are Catherine Maresh, Vice President and Chief Intellectual Property Counsel at Immersion, Elizabeth McCombs, Senior Vice President for Medical Segment Research and Development at BD, Erin Byrne, Vice President and Chief Technology Officer for Data and Devices at TE Connectivity and Ed White, Head of Analytics for the IP Group at Clarivate. See acast.com/privacy for privacy and opt-out information.

Introducing the 'Ideas to Innovation' podcast from Clarivate. Learn more about Clarivate and what's coming up in the episodes that will follow. See acast.com/privacy for privacy and opt-out information.

Clarivate Plc, Q1 2021 Earnings Call, Apr 29, 2021

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Caroline Loew, President and CEO from Glympse Bio. They discuss the biotech's focus on both disease detection and response to treatment using bioengineered sensors, starting with NASH. Dr. Loew also shares career advice for moving from pharma to biotech and how she pivoted the company's narrative during a funding round at the bottom of the pandemic-related stock market crash. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Leen Kawas, president and CEO of Athira Pharma. Dr. Kawas shares the company's innovative approach to treating Alzheimer's disease by developing small molecules to restore neuronal health and stop neurodegeneration. They also discuss Athira's recent IPO following a successful series B funding round, all during the pandemic.  See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, high definition, protein biomarker profiles. Although their launch plans were disrupted by the pandemic, Bryan shares how Adarza responded to the challenge by utilizing Ziva for COVID-19 research. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Brian Culley, CEO of Lineage Cell Therapeutics. Brian and Mike discuss the company's cell therapy program, utilizing pluripotent stem cells, initially targeting dry age-related macular degeneration, acute spinal cord injuries, and non-small cell lung cancer. Brian shares about the status of their Phase 1/2a clinical trials, and how COVID-19 has affected the company's operations. See acast.com/privacy for privacy and opt-out information.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Jonathan Javitt, CEO of NeuroRx. Dr Javitt discusses how NeuroRx is working in collaboration with Relief Therapeutics on Aviptadil, a synthetic version of vasoactive intestinal peptide, and a potential treatment of COVID-19 related respiratory failure. Dr. Javitt shares the promising results of an open label study of the drug, and the company's plans if trials are successful. See acast.com/privacy for privacy and opt-out information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, Part of Clarivate talks to Bob Coughlin, president and CEO of the Massachusetts Biotechnology Council. Bob provides insights from what is unarguably the world's number one biopharma hotspot. Bob and Mike discuss how the industry has collaborated to counter the most immediate issues the COVID-19 pandemic has raised and how these could inform the future of biopharma. Bob also talks passionately about how partnering with patient groups is key to patient centricity to truly understand the real unmet patient need.  See acast.com/privacy for privacy and opt-out information.

Support for a federal privacy law is gaining bipartisan momentum, but policymakers must consider the burdens that excessive regulation can place on consumers, trademark owners, and even law enforcement. Existing privacy laws in California, Europe, and beyond have had mixed effects. How can they help inform the creation of federal privacy legislation in the US? On this episode, https://www.aei.org/profile/shane-tews/ (Shane) is joined by https://www.linkedin.com/in/brianjamesking/ (Brian King), Director of Internet Policy and Industry Affairs at https://clarivate.com/ (Clarivate) and a representative of the Intellectual Property Constituency at the https://www.icann.org/ (Internet Corporation for Assigned Names and Numbers) (ICANN). Together, they discuss how privacy regulations have created legal access challenges to the information that users of data need for compliance with trademark and intellectual property rules, public safety laws, and privacy policies.  

Fast-Tracking a CoV-19 Vaccine: Why Should We Worry? Richard Gale and Gary Null PhD Progressive Radio Network, May 21, 2020   The CoV-19 pandemic is now exposing the hidden agendas and motives of the powers that be in government, in the pharmaceutical industry and Wall Street, and in the media. Despairingly opponents of vaccine mandates are largely divided. Many Trump supporters in the so-called anti-vaccination community believed he would be their savior to protect vaccine exemptions and avert compulsory mandates. Nevertheless, during his watch draconian mandate laws to ban religious exemption for children to attend public schools have been signed by the governors of California and New York. Throughout the CoV-19 pandemic, Trump has waffled wildly, jumping on and off the vaccine band wagon depending upon his daily whims. Early he stated there was no need for a vaccine since the virus would magically disappear and no longer be a threat. It was his gut feeling and not surprisingly he was wrong. Yet during a press conference on March 14th, Trump announced the unveiling of his Operation Warp Speed agenda to accelerate development of a CoV-19 vaccine and have it ready this year. Trump is now fully on board with the pro-vaccination agenda. Moreover, he ordered that the military will be "mobilized so at the end of the year, we're going to be able to give it to a lot people very, very rapidly."  His newly appointed Warp Speed advisor is a venture capitalist and a former chairman of GlaxoSmithKline's vaccine division, Moncel Slaoui. Often in order to understand Trump's strategies, follow the money trail, especially if the money trails leads to sealing loyalty to the president. However, his probable immediate motivation is for reelection and to increase the profits of pharmaceutical and investor profiles as repayment for those loyalties.  We can therefore reasonably expect, despite what has already been stated, that Trump may nationally mandate a CoV-19 vaccine. There are voices in Trump's camp who favor mandates. One of Trump's leading attorneys is Harvard law professor Alan Dershowitz who recently went on record saying, "Let me put it very clearly, you have no constitutional right to endanger the public and spread disease.... You have no right not to be vaccinated, you have no right not to wear a mask, you have no right to open up your business.... if you refuse to be vaccinated, the state has the power to literally take you to a doctor's office and plunge a needle into your arm." What might be the downside if a vaccine pushed on the public en masse is discovered to not work or is found unsafe in the long-term? Worse, what might be the consequences of a flawed vaccine that becomes mandated and required as policy to attend schools, work or even to leave the home to shop? We might be faced with an epidemic of vaccine-related illnesses and death on a scale that could dwarf the current CoV-19 pandemic. There would be a greater rationale to push forward a fast-tracked vaccine if the private vaccine manufacturers were held legally liable for vaccine-related injuries and deaths. However, this was laid to rest by the Reagan administration after the passage of the Vaccine Injury Compensation Act in 1986, which freed the pharmaceutical industry from personal injury lawsuits. Consequently, there is no incentive whatsoever for the vaccine industry to perform thorough due diligence analyses and reviews and to adopt gold standard scientific measures to create a safe and effective vaccine. In effect, they have free rein to develop vaccines according to their own rules. According to German oncologist Claus Kohnlein, we may well be in the era of "virus mania."  The prevailing medical establishment has become dominated by a rapidly expanding private industry obsessed with viruses and the invention of pandemics for enormous profit. This obsession has hijacked not only medical practice and legislators who are determined to mandate vaccination, but has also infiltrated the entire mainstream media. This is despite consensual confirmatory evidence that some of these viruses may not be dangerous enough to warrant a vaccine nor demand mass screening to monitor potential infection.  For example, University of Toronto professor emeritus of pathology, Dr. Etienne de Harven would have us ask: do molecular markers for retroviruses truly confirm the presence of a virus, or is this a human invention that substitutes the absence of identifiable viral proteins and particles? Embedded in all of the confusion over CoV-19 and the heated debates and uncertainty over life returning to normal, the mainstream chorus chants that stability will only resume after a vaccine is launched on the public. At this moment, Kohnlein's 2007 book Virus Mania: Avian Flu, Cervical Cancer, SARS, BSE, Hepatitis C, AIDS, Polio is essential reading to expose the life-threatening failures in modern medical science's efforts to tackle viral threats. And what Kohnlein outlines is being repeated again with CoV-19. The need for a vaccine in order for society and the economy to return to normal was clearly stated by Trump's Federal Reserve Chairman Jerome Powell. ".. for the economy to fully recover," he stated, "that may have to await the arrival of a vaccine." Unfortunately, besides the White House and nation being impatient and placing high hopes in a vaccine, we are also witnessing a careless zeal to cut regulatory corners. And this atmosphere could potentially end in a serious medical disaster on the not-too-distant horizon.  Virus mania is morphing into vaccine mania. That vaccine mania has become a reality is evidenced in the 133 vaccines currently in development worldwide targeted against CoV-19 according to the Milken Institute. Many challenges must be recognized and surmounted before an effective CoV-19 vaccine can be deemed safe..  The virus has already been shown to mutate rapidly despite beliefs that its RNA is stable. .Mutations of course naturally occur when a virus changes hosts, especially after jumping species. However, RNA viruses mutate more readily than larger DNA viruses such as herpes, HPV and smallpox.  University of Cambridge has identified three separate mutations since the Wuhan outbreak. Last month Los Alamos National Laboratory reported a recent mutation that is more contagious and transmittable than the original Wuhan strain.  Another strain was identified in India; the South China Morning Post reported that this Indian strain is being viewed as more virulent for the development of severe acute respiratory syndrome. The researchers from National Changhua University in Taiwan and Murdoch University in Australia warned that it "means current vaccine development against Sars-CoV-2 is at risk of becoming futile." The problem with mutations, similar to the challenges to create a universal flu vaccine, is whether or not any CoV-19 vaccine would generate sufficient immunity to combat future mutant strains and whether this is a cross-over of multi-strain immunity. Furthermore, some reports indicate that natural CoV-19 immunity may wane quickly.  This is an additional caution about any promises that a fast-tracked and poorly evaluated vaccine, which will bypass a rigorous regulatory review, will provide much if any long-term immunity. In a preliminary study, Columbia University researchers identified people who were reinfected with the same coronavirus strain within a single year. Twelve individuals tested positive two or three times for the same strain within 18 months.  Similar findings were noted in South Korea. The Columbia scientists' conclusion is that coronavirus "immunity seems to wane quickly."  Dr. Matthew Frieman at the University of Maryland is an expert in coronaviruses.  He states that "we get coronaviruses every winter even though we're seroconverted..... We really don't understand whether it is a change in the virus over time [ie., mutations] or antibodies that don't protect from infection." The consequences are that proposals for issuing immunity certificates or passports would be utterly futile, an extraordinary waste of funding and that would accomplish little. Since 2003 efforts have been made to develop coronavirus vaccines following the first SARS outbreak in China. All of these efforts failed either because of a lack in funding or because of observable serious adverse effects that necessitated the project to cease. To our knowledge, none of these efforts reached human trials because of serious adverse effects in animal trials. However, now we are witnessing one company Moderna bypassing animal studies with its new CoV vaccine and commencing with human trials. The company has already reported that its experimental vaccine showed signs of being "safe and provoked a strong immune response" in a first phase clinical trial; the vaccine was administered to a very small number of human participants (N=45) to determine safety and to measure the levels of volunteers' immune response. Just over half of the participants had recognizable antibodies, but these were "binding antibodies." What is critical for protection is neutralizing antibodies; and on this account only 4 of the 45 participants were actually "analyzed" to show promising neutralizing antibody results. Nor did Moderna report any T-cell activity, essential for fighting the virus. In other words, Moderna's premature reports are negligible for guaranteeing an effective and safe CoV-19 vaccine. We should remember this is only a first phase trial. The vaccine has a ways to go before it can be ruled effective. "If you look at vaccine development," stated Dr. Daniel Salmon, Director of Johns Hopkins' Institute for Vaccine Safety, "[there are] lots of vaccines that look good out of phase one that don't turn out to be good products." Prof. Michel Chossudovsky, a professor emeritus at the University of Ottawa, has documented NIAID's Dr. Anthony Fauci's support of Moderna's vaccine, and. according to Bobby Kennedy, Faico waved the needs for the company to test the vaccine in ferrets and primates and instead proceed directly into larger human trials. Both Moderna's and its German competitor CureVac's CoV-19 vaccine rely on mRNA technology, which carry strands of mRNA that encode CoV-19-specific proteins intended to stimulate the immune system to produce antibodies. Bill Gates says he is "particularly excited by two new approaches that some of the candidates are taking: RNA and DNA vaccines." But modern medicine has no practical experience with such vaccines being given to entire populations; therefore, there is absolutely no past history to monitor potential long-term risks, such as whether an engineered genetic code of a viral antigen will recombine adversely with the body's own DNA and trigger other life-threatening injuries we have to be aware of. Despite the hype over Moderna's apparent success and a huge 39 percent rise in its stock price, a recent article in Nature warns us not to pop the Champaign corks yet. Moderna's data remains unpublished and many scientists worry the results may be "murky." It is worrisome that the company would make such an announcement before any data is made available for independent review. Seemingly this was solely for financial reasons; Moderna's premature claims were rewarded with a $1.3 million stock offering to bankroll its vaccine. Trump is also throwing his weight behind Moderna's vaccine: it is manufactured in the US, funded by the government, and Warp Speed advisor Slaoui sits on the board of the Lonza Group that is collaborating with Moderna. One caveat is that Moderna has never brought a vaccine nor a therapeutic product to the market and is therefore largely inexperienced. There is also no public release of consent forms that the trial participants are required to sign. And no indication of how much volunteers were paid. Are they being compensated with inordinate amounts beyond the industry's standards to accept high risk? None of this information has been provided. The Nature article also quotes Baylor University vaccine scientist and coronavirus expert Dr. Peter Hotez's response to Moderna's announcement, "I'm not convinced that this is really a positive result."  The article notes that "... most people who have recovered from COVID-19 without hospitalization did not produce high levels of ‘neutralizing antibodies', which block the virus from infecting cells. Moderna measured these potent antibodies in eight participants and found their levels to be similar to those of recovered patients." The most promising vaccine, Hotez believes, is being developed by Sinovac Biotech in China, but it requires three separate inoculations. Sinovac's vaccine after being administered to rhesus monkeys showed no presence of the virus found in the throats, lungs or rectums of the primates. Another vaccine being developed at Oxford University protected monkeys (only six in the trial) from pneumonia but the primates;' nasal passages contained as much of the virus as those unvaccinated. In other words, all vaccinated monkeys became infected. In addition, the antibody titers were extremely low, which suggests the animals may not be fully protected. Nevertheless, Oxford is interpreting these weak results as a success and will also push forward with recruiting participants for a large human trial. This sets a very disturbing precedent that will likely be imitated by other vaccine companies either now or during a future infectious pandemic.  Still other vaccines in development are entirely experimental and have no predecessor on the market. Noroavx has created a recombinant nanoparticle vaccine -- an artificially engineered fake replica of the actual virus. Since there is no vaccine on the current CDC schedule utilizing this technology, we have no idea of its long-term safety.  So what do earlier efforts at developing a coronovirus vaccine tell us? In 2012, a vaccine being developed by the University of Texas at Galveston and Baylor University observed pulmonary immunopathology in an animal study with mice. The researchers proposed the vaccine's pathology may be attributed to an adverse cytokine response, an observation a large number of physicians and researchers have made with persons severely affected with CoV-19.  A later vaccine effort in 2016 by the same institutions targeted the MERS coronavirus strain and observed lung immunopathology similar to infection with the wild virus. A year earlier, another vaccine effort led by the University of North Carolina's Vaccine Institute noted an increase in eosinophilic proinflammatory pulmonary responses in a mouse model. Eosinophils are a type of white blood cell that are associated with infections, allergies and cancers. However, an abnormal increase in eos, a condition called eosinophilia, can result in nasal allergies and even cancer. This raises a question whether the North Carolina vaccine could have potentially contributed to lung cancer? The vaccine was also shown to provide poor protection from infection both in the adjuvant and non-adjuvant vaccines. A later 2018 SARS vaccine trial with rhesus macaques conducted at Wuhan University led to antibody-dependent vaccine induced infections. The project was supposedly discontinued. Another SARS vaccine trial with ferrets led by researchers at the University of Manitoba observed a promising neutralizing antibody response; however there severe inflammatory responses were observed in the animals' livers. The scientists concluded that the vaccine was "associated with enhanced hepatitis." That vaccine project too seems to have been shelved. Japanese scientists in 2008 developed a SARS vaccine that utilized a recombinant vaccinia virus that expressed the SARS spike protein. Immunized mice exhibited increased infiltration of esoinophils in the lungs, a thickening of the alveolar epithelium, an uptake in cytokines contributing to abnormal inflammatory storms, and aggravated severe pneumonia. Clearly, the past history to develop a coronavirus vaccine is not encouraging. Jennifer Sun, a molecular biologist at Princeton, warns that due to past coronavirus vaccine failures, the CoV-19 signatures need to be fully evaluated before any human trials commence in order "to prevent organ damage upon viral challenge." Baylor University, which has attempted to develop a vaccine, knows the problems all too well. According to Dr. Robert Atmar at Baylor's Department of Molecular Virology,  coronaviruses "are notoriously difficult when it comes to vaccine development.... the concern is that if these vaccines were used in people, they could end up causing harm." Other scientists have issued warnings against hastily approving a vaccine without proper large, long-term clinical trials and scrupulous evaluation. For example, Dr. Paul Offit at the Children's Hospital of Philadelphia and one of the nation's most vocal advocates for compulsory vaccination, has criticized the shortened vaccine timelines being stated. In a Philadelphia Inquirer interview, Offit cautioned for the need of "extensive animal model testing" to be certain the vaccine "is safe in animals." This process, Offit says, "takes a lot of time, typically years."  "If you're going to be testing this in otherwise healthy people who are very, very unlikely to die from this infection," he continues, "you better make sure it's safe. So you want those regulations in place.... The point being: We're not very good at assessing risk." Trump is pushing to have a vaccine ready by the end of this year. Offit and others argue two years is more realistic, and the global analytics firm Clarivate estimated that a vaccine "will require at least five years... to complete the development process through full regulatory approval." The good news is that the firm predicts that Moderna's mRNA vaccine has a 5% probability of success. The bad news is that the government and federal health agencies will very likely ram the first promising vaccine through the regulatory channels without having been properly evaluated for its efficacy and safety. Without serious critical thought, the demand for a vaccine now outweighs the risks. And there is the potential for many risks that remain completely unknown, which is the same for any vaccine. Trump said it will be available "in a fairly quick manner."  In an interview with philosophy professor Nicholas Evans at the University of Massachusetts, he raised concerns over the lack of proper animal model vaccine trials before administering it to humans. Unfortunately there are no US laws that require animal trials. Consequently the pharmaceutical companies are taking advantage of this derelict oversight in their race to be the first to get a vaccine approved and distributed. Evans also worries about "the shredding of regulations and regulatory norms as part of their [the federal health agencies] response to this outbreak and this is a very dangerous proposition." Rarely do politicians, and increasingly more and more scientists, make efforts to learn the lessons history offers.  Past efforts to develop a coronavirus vaccine have failed and the adverse effects observed in these efforts are clear indicators for why fast-tracking a CoV-19 vaccine would be frightfully irresponsible. But now this is all being ignored within the Trump White House, the CDC, and across most of the medical establishment, particularly the private vaccine makers. In addition, the media continues to fuel our vaccine mania, priming the public to willingly surrender their bodies to the syringe under a pretext of being protected from future CoV outbreaks. Perhaps the most disturbing problem our national public health faces is the failure of our leading health agencies -- the CDC, the National Institute of Allergy and Infectious Disease, and the World Health Organization -- to acknowledge the overwhelming evidence that no vaccine developed during the past half century is truly safe and effective for all.  Are there any scientific gold standard studies -- double blind, controlled trials using an actual inert placebo -- conducted for any vaccine currently on the market?  No? Have meticulous independent studies been performed to compare the quality of health between vaccinated and non-vaccinated participants?  Unfortunately there aren't any, and the CDC was forced to acknowledge this during a Congressional subcommittee hearing on autism. All of the media's vaccine propaganda is stacked with pro-industry scientists who have something to gain. They are always presented as the experts. On the other hand, independent scientists, as well as board certified physicians and pediatricians, who question the official vaccine dogma, are attacked by federal officials and the mainstream media as alarmists, anti-vaxxers and even threats to society if they speak out.  Several years ago the World Health Organization listed vaccine opponents among the 10 leading threats to global health. But no one considers that the many millions of people who either themselves or their children received a vaccine and experienced serious adverse effects were at one time pro-vaccination. It was for that very reason they submitted themselves to be vaccinated in the first place.  Now with the dramatic rise in vaccine injuries and deaths as more shots are added to the nation's vaccination schedule, we still await Congressional hearings at the federal and state levels that invite independent scientists, toxicologists and immunologists to explain the actual peer-review literature that would have us conclude there is no such thing as either a safe vaccine or vaccine that creates neutralizing antibodies for any given person. In other words, every vaccine may or not be effective and there is no proof they protect everyone.   There is also the utterly absurd notion that whenever someone receives a vaccine and does not come down with the disease, 100 percent of the credit is given to the vaccine's efficacy. And where are the real advocates who are speaking on behalf of the victims from vaccine injuries?  Certainly not the pharmaceutical industry that profits immensely without any liability for damages. Nor are advocates to be found in federal and state health agencies, in most of the medical community nor across the spectrum of the media. Rather, those who refuse to take unsafe vaccines are blamed for spreading fear, uncertainty, conspiracies and even infectious disease. But now those who have been injured or their loved ones are speaking out in greater unison. This is becoming increasingly uncomfortable for those who have profited for years from their pain. 

A puzzle that may baffle the inquiring mind is how a college dropout, a computer nerd without any notable biological or medical background, and at one time the wealthiest person in the world before being unseated by the self-centered playboy Jeff Bezos, could rise to become one of humanity's leading spokespersons about vaccination. After transitioning away from Microsoft to work full time for his Bill and Melinda Gates Foundation in 2006, funding vaccine development and agricultural genetic engineering seems to have turned into one of Bill Gates' deeper passion. in the past, he has been a public protector of Monsanto's chemical-dependent GMOs and continues to promote the agro-chemical paradigm throughout the developing world. Although there is nothing wrong with philanthropic enterprises for causes we believe in, what is disturbing is that a non-medical expert has assumed the role of being a national thought leader on vaccination safety and policy. What people do is less important than their motivations and intentions.  Personality- wise, it is no secret that Gates was a difficult boss to work with. He was known to be extremely critical, belligerent, sarcastic and his anger would often degrade employees. He was a fierce taskmaster as the Washington Post reported, and Fortune magazine listed him as an "egotistical jerk" along with other billionaires such Steve Jobs and Jeff Bezos.  Now with COVID-19 upon us, some, such as NPR, would call Gates prophetic for warning about viral pandemics five years ago. However, there is nothing extraordinarily novel, and definitely not Delphian, in this pronouncement. Gates is certainly no oracle. As personal experience confirms, such conversations among scientists have gone on in the corridors and cafeterias of biotech firms for over three decades. More likely is Gates simply fear mongering to turn his enormous investments into vaccine research and development for a coronavirus vaccine with the outcome being greater profits? To call Gates a vaccine and genetic engineering fanatic is an understatement. While lecturing at the elitist TED 2010 conference in Long Beach, CA, he slipped a statement while speaking about the dangers of climate change and over population: “Vaccines? I love them.” His admission was made in the context of his philanthropic strategy and vaccines play a crucial role in his firm conviction that population reduction is an urgent priority for the survival of humanity. Of course the question that arises is who should be eliminated from the population? And who is elected from the public to make such decisions? The short answer is no one. Nevertheless this agenda is covertly proceeding through foundations, international agencies, non-profits, and private industry. In 2000, the Gates Foundation founded the International Finance Facility for Immunization (GAVI) and that organization's Global Fund for Children's Vaccines. GAVI is a global collaboration that includes governments health ministries, the Rockefeller Foundation, the World Bank, WHO, the International Federation of Pharmaceutical Manufacturers, UNICEF, corporate vaccine makers, and other influential entities. All of these are zealot vaccination promoters. One of the organization's goals is to vaccinate every child in Africa. In 2019, GAVI reported having reached over 960 million campaign immunizations in developing countries.  In his deconstruction of Bill Gates' charitable agenda, F. William Engdahl writes, “Vaccinating a child who then goes to drink feces-polluted river water is hardly healthy in any respect. But of course cleaning up the water and sewage systems of Africa would revolutionize the health conditions of the Continent.” Far more effective would be the Foundation donating its billions to improve sanitation and hygiene, and provide nutrition to the 2.6 billion people who have little to none, for increasing clean water sources so 900 million global residents can have access to drinkable water (now at 1 in 3 Africans). Instead, the Foundation could be funding thousands of health clinics focusing on the chronic illnesses these populations suffer from most. This is simply common sense. “Bad water,” says the Stockholm International Water Institute's director, Anders Bentell, “kills more people than HIV, malaria and war together.”  And globally, contaminated water, which kills approximately 9 million people annually, is a far more serious crisis than the evidence now indicates for coronavirus.  Over the past several years, the prestigious British medical journal The Lancet has printed a series of in-depth analyses of the Gates Foundation with disturbing revelations. In a September 2008 article, “Misfinancing Global Health: A Case for Transparency in Disbursements and Decision Making,” the authors' investigation came to the conclusion that aside from excessive funding of high profile Western institutions and organizations, there was “a heavy bias in funding towards malaria and HIV/AIDS, with relatively little investment into tuberculosis, maternal and child health, and nutrition–with chronic diseases being entirely absent from its spending portfolio.” And a later study by Dr. David McCoy from the Center for International Health found that “the grants made by the Foundation do not reflect the burden of disease endured by those in deepest poverty.” None of these findings have been covered to any extent by mainstream media nor any governing body. Seemingly Gates is riding on the coat tails of the COVID-19 panic that has infected much of the global community, when in fact, some analyses, such as one recently out of Stanford, indicate that the danger is likely over exaggerated. Earlier this month, Gates announced he would be spending billions of dollars to fund seven separate coronavirus vaccine development initiatives. As a result, his Foundation has emerged as perhaps the foremost leader in the vaccine industry's response to the pandemic. Gates has gained free entrance into the offices and boardrooms of all the leading players savoring the opportunity to launch a fast-tracked coronavirus vaccine that may likely be made mandatory for Americans, including National Institutes of Allergies and Infectious Disease director Anthony Fauci, the CDC's vaccine advisory committee and the WHO. Thus far, Gates has shown reservation against a hasty launch of a vaccine that will likely not have been reviewed long enough to determine its safety and efficacy in long-term immunity. During a White House press conference with Trump, Fauci indicated a vaccine might take a year or two before approval. The anti-science Trump replied he would prefer it were a couple months. There is a strong possibility that like the influenza vaccine, immunity will wane quickly. We may recall that Fauci aggressively pushed for fast-tracking the H1N1 flu vaccine during the swine flu epidemic that never appeared as predicted. He was called out on this failure by Senator Tom Coburn for advocating a vaccine found to be only 30% effective in trials conducted in Thailand. Recent studies out of Shanghai already show that 30 percent of those who contract a wild COVID-19 virus show only minor or no neutralizing antibodies. And South Korea is now reporting cases of individuals getting infected with COVID-19 a second time. Other seasonal coronaviruses, which are only mild common colds, return repeatedly and indicate infection triggers only short temporary immune responses and even then not in everyone. However, not all leading vaccine advocates are on board with rushing a vaccine. During a Philadelphia Inquirer interview with rotavirus vaccine inventor Dr. Paul Offit at the Children's Hospital of Philadelphia, Offit warned against efforts being made to get a vaccine on the market as swiftly as possible. This is a virus, according to Offit, that we still know very little about. He stated, "If you're going to be testing this in otherwise healthy people who are very, very unlikely to die from this infection, you better make sure it's safe." He offers the example of the poorly developed dengue vaccine that was tested in Latin America and the Philippines and found to increase the risk of dengue shock syndrome. The same could happen with a COVID-19.  Peter Hotez, Dean of the National School of Tropical Medicine at Baylor University, developed a vaccine against SARS in 2016 before money dried up. Yet in a recent appearance before Congress, he testified a coronavirus vaccine could have a "unique potential safety problem."  We should be warned that questions would remain if and whether Hotez's team were to get a vaccine into advanced trials. An earlier University of Texas effort to develop a vaccine against the SARS coronavirus was appalling. Despite inducing neutralizing antibodies, all the mice in the trial exhibited immunopathological events in the lungs. More recently, a global analytics firm, Clarivate, investigated two COVID19 vaccines in the pipeline that have reached later clinical trials. Their report estimates that it will require over 5 years for developing a safe vaccine and it will likely be only 5 percent effective. In other words, it is an enormous waste of funding.  Gates, on the other hand, seems to be ignoring these warnings from persons who have devoted their lives to vaccine development. He is stubbornly determined, irrespective of money spent, to get a COVID19 vaccine onto the market. A question that arises in our minds is how concerned Gates might be of vaccine safety issues. If the past is any indication of his priorities, it appears his focus is to increase vaccine compliance while ignoring the high incidence of serious adverse events and deaths. Bobby Kennedy Jr. at the Children's Health Defense organization has listed some of the vaccination debacles that are directly associated with his Foundation: In 2002, operatives in the Gates network enforced a meningitis campaign in Sub-Sahara Africa that paralyzed up to 500 children. In 2010, his foundations support for Glaxo's experimental malaria vaccine trials killed 151 African infants and seriously injured another 1,000.  Gates collaboration with India's National Technical Advisory Group resulted in a catastrophe of unmonitored overlapping polio immunization programs triggering an epidemic of non-polio acute flaccid paralysis that affected 490,000 children. Gates vaccine programs were forced to leave India. Cases of vaccine derived polio now outnumber cases from wild polio.  In 2014, Foundation funds went to experimental HPV vaccine trials in India, in joint collaboration with Glaxo and Merck, that violated ethical standards. Over 1,000 girls developed severe autoimmune diseases and fertility disorders.  It is easy to overlook the larger significance of the results Gates' vaccination campaigns. In short, Gates was responsible for implementing and funding these programs that injured and caused the deaths of innocent children and adults. Due to his stature among governmental and international health agencies, he has not been held accountable. People such as Gates are judged by a different standard, meaning they are not judged at all. Equally worrisome, aside from his vaccine frenzy, Gates makes efforts to influence the nation's health policies. In the past he has been a fanatical advocate for mandatory vaccination.  During a recent TED Talk interview, Gates advocated a national campaign to issue certificates for those who have been either infected with COVID-19 or vaccinated against it. "Eventually what we'll have to have is certificates of who's a recovered person and who's a vaccinated person," he stated, "because you don't want people moving around the world... (without their certificates)." Gates however is a symptom of another side of national crisis. There would be no need for citizen billionaires to be taking the helm to manipulate national policy responses to health crises, such as the COVC-19 pandemic, if there was in place a functioning healthcare system. Unfortunately it has been the gross failures of the Trump and previous presidential administrations that have opened the doors for others like Gates to step in. For too long, the US's federal health agencies have been thoroughly compromised and corrupted by private pharmaceutical interests. The pandemic is revealing to Americans that we have the most dysfunctional medical system in the developed world.  Unfortunately the wealthiest elite on the planet are rarely questioned about the correctness of their actions and schemes. As long as a Bill Gates says he is giving huge sums of money to a cause to end disease and suffering, we are not suppose to probe further. Rather, in the case of mainstream media, such people are to be worshiped as saviors. The oligarchic elite are so well interconnected on multiple boards of directors, clubs for the rich and powerful, think tanks, media conglomerates, and among the high ranks of elected legislators and politicians that it is difficult to have an open and honest debate on the merits of their actions and spending.  So when someone like Ted Turner says we should reduce the world's population by more than half, and Bill Gates suggests a 15 percent reduction, do we fully understand the potential for eugenic efforts?  And this is another issue about Gates that should disturb every person on the planet.  As a keynote speaker at the TED 2010 conference, Gates laid out his rationale for an international effort towards global depopulation. He said, “If we do a really great job on new vaccines, health care, reproductive health services, we could lower that [projected to be 9 billion people by 2050] by perhaps 10 or 15 percent.“ Therefore it was shocking to learn that a tetanus vaccine administered to Kenyan women in child bearing years was purportedly laced with Human Chorionic Gondatropin (hCG) that causes miscarriage and renders a woman sterile. The discovery was made by the Kenyan Catholic Doctors Association that noted something was seriously wrong with women following vaccination and had the vaccine analyzed. But more appalling was tracing the vaccination campaign to funding by the Bill and Melinda Gates Foundation for distribution by UNICEF. Further evidence is found in a 2005 Foundation press release stating Gates' gift of $26 million to UNICEF for a vaccine to eliminate maternal and neonatal tetanus. Curiously, Brian Shilhavy at Health Impact News observed, "there was no outbreak of tetanus in Kenya, on the perceived threat of tetanus due to local flood conditions." Therefore, why the campaign to vaccinate young women en masse? In conclusion, we have the world's second richest billionaire who deeply believes he has a personal authority to be a policy maker for America's public health. Therefore, do we truly realize the dangers of billionaires, unelected to any position of authority over the nation, and their threats that undermine democracy?